HUMAN METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES (HMR4, HMR6, HMR7) AND RELATED DNA COMPOUNDS

Abstract: The present invention relates to human metabotropic glutamate receptor (hmGluR) proteins, isolated nucleic acids coding therefor, host cells producing the proteins of the invention, methods for the preparation of such proteins, nucleic acids and host cells, and uses thereof. Furthermore, the invention provides antibodies directed against the hmGluR proteins.

Description: HUMAN METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES (HMR4, HMR6, HMR7) AND RELATED DNA COMPOUNDS. The present invention relates to human metabotropic glutamate receptor (hmGluR) proteins, isolated nucleic acids coding therefor, host cells producing the proteins of the invention, methods for the preparation of such proteins, nucleic acids and host cells, and uses thereof. Furthermore, the invention provides antibodies directed against the hmGluR proteins of the invention. Metabotropic glutamate receptors (hmGluR) belong to the class of G-protein (guanine nucleotide binding protein) coupled receptors which upon binding of a glutamatergic ligand may transduce an extracellular signal via an intracellular second messenger system such as calcium ions, a cyclic nucleotide, diacylglycerol and inositol 1,4,5-triphosphate into a physiological response. Possessing seven putative transmembrane spanning segments, preceded by a large extracellular amino-terminal domain and followed by a large carboxy-terminal domain metabotropic glutamate receptors are characterized by a common structure. Based on the degree of sequence identity at the amino acid level the class of mGluR can be divided into different subfamilies comprising individual receptor subtypes (Nakanishi, Science 258, 597-603 (1992)). Each mGluR subtype is encoded by a unique gene. Regarding the homology of an individual mGluR subtype to another subtype of a different subfamily, the amino acid sequences are less than about 50 % identical. Within a subfamily the degree of sequence identity is generally less than about 70 % . Thus a particular subtype may be characterized by its amino acid sequence homology to another mGluR subtype, especially a subtype of the same mammalian species. Furthermore, a particular subtype may be characterized by its region and tissue distribution, its cellular and subcellular expression pattern or by its distinct physiological profile, e.g. by its electrophysiological and pharmacological properties. The amino acid L-glutamate being the major excitatory neurotransmitter, glutamatergic systems are presumed to play an important role in numerous neuronal processes including fast excitatory synaptic transmission, regulation of neurotransmitter releases, long-term potentation, learning and memory, developmental synaptic plasticity, hypoxic-ischemic damage and neuronal cell death, epileptiform seizures, as well as the pathogenesis of several neurodegenerative disorders. Up to today, no information is available on human metabotropic glutamate receptor (hmGluR) subtypes, e.g. on their amino acid sequence or tissue distribution. This lack of knowledge particularly hampers the search for human therapeutic agents capable of specifically influencing any disorder attributable to a defect in the glutamatergic system. In view of the potential physiological and pathological significance of metabotropic glutamate receptors, there is a need for human receptor subtypes and cells producing such subtypes in amounts sufficient for elucidating the electrophysiological and pharmacological properties of these proteins. For example, drug screening assays require purified human receptor proteins in an active form, which have not yet been attainable. It is an object of the present invention to fulfill this need, namely to provide distinct hmGluR subtypes, nucleic acids coding therefor and host cells producing such subtypes. In particular, the present invention discloses the hmGluR subfamily comprising the subtype designated hmGluR4, and the individual proteins of said subfamily. In the following, said subfamily will be referred to as the hmGluR4 subfamily. Contrary to other hmGluR subtypes the members of this subfamily are potently activated by L-2-amino-4- phosphobutyric acid (AP4) and, when expressed e.g. in Chinese hamster ovary (CHO) cells or baby hamster kidney (BHK) cells, negatively coupled to adenylate cyclase via G protein. Using a system comprising a recombinant hmGluR subtype of the invention in screening for hmGluR reactive drugs offers (among others) the possibilities of attaining a greater number of receptors per cell giving greater yield of reagent and a higher signal to noise ratio in assays as well as increased receptor subtype specificity (potentially resulting in greater biological and disease specificity). More specifically, the present invention relates to a hmGluR subtype characterized in that its amino acid sequence is more than about 65 % identical to the sequence of the hmGluR4 subtype having the amino acid sequence depicted in SEQ ID NO:2. According to the invention the expression "hmGluR subtype" refers to a purified protein which belongs to the class of G protein-coupled receptors and which upon binding of a glutamatergic ligand transduces an extracellular signal via an intracellular second messenger system. In such case, a subtype of the invention is characterized in that it modifies the level of a cyclic nucleotide (cAMP, cGMP). Alternatively, signal transduction may occur via direct interaction of the G protein coupled to a receptor subtype of the invention with another membrane protein, such as an ion channel or another receptor. A receptor subtype of the invention is believed to be encoded by a distinct gene which does not encode another metabotropic glutamate receptor subtype. A particular subtype of the invention may be characterized by its distinct physiological profile, preferably by its signal transduction and pharmacological properties. Pharmacological properties are e.g. the selectivity for agonists and antagonist responses. As defined herein, a glutamatergic ligand is e.g. L-glutamate or another compound interacting with, and particularly binding to, a hmGluR subtype in a glutamate like manner, such as ACPD (1S,3R-1 -amino _yclopent_neJ,3-dicarboxylic acid), an ACPD-like ligand, e.g. QUIS (quisqualate), AP4, and the like. Other ligands, e.g. (R,S)-α-methylcarboxyphenylglycine (MCPG) or α-methyl-L-j _P 4, may interact with a receptor of the invention in such a way that binding of glutamatergic ligand is prevented. As used hereinbefore or hereinafter, the terms "purified" or "isolated" are intended to refer to a molecule of the invention in an enriched or pure form obtainable from a natural source or by means of genetic engineering. The purified proteins, DNAs and RNAs of the invention may be useful in ways that the proteins, DNAs and RNAs as they naturally occur are not, such as identification of compounds selectively modulating the expression or the activity of a hmGluR of the invention. Purified hmGluR of the invention means a member of the hmGluR4 subfamily which has been identified and is free of one or more components of its natural environment. Purified hmGluR includes purified hmGluR of the invention in recombinant cell culture. The enriched form of a subtype of the invention refers to a preparation containing said subtype in a concentration higher than natural, e.g. a cellular membrane fraction comprising said subtype. If said subtype is in a pure form it is substantially free from other macromolecules, particularly from naturally occurring proteinaceous contaminations. If desired, the subtype of the invention may be solubilized. A preferred purified hmGluR subtype of the invention is a recombinant protein. Preferably, the subtype of the invention is in an active state meaning that it has both ligand binding and signal transduction activity. Receptor activity is measured according to methods known in the art, e.g. using a binding assay or a functional assay, e.g. an assay as described below. Preferred hmGluR subtypes of the hmGluR4 subfamily are subtypes hmGluR4, hmGluR7 and hmGluRό. A particularly preferred hmGluR4 subtype is the protein having the amino acid sequence set forth in SEQ ID NO:2. A hmGluR7-type protein may comprise a polypeptide selected from the group consisting of the polypeptides having the amino acid sequences depicted in SEQ ID NOs: 4, 6, 8 and 10, respectively. Such hmGluR7 subtype is preferred. Particularly preferred are the hmGluR7 subtypes having the amino acid sequences set forth in SEQ ID NOs: 12 and 14, respectively. A preferred hmGluR6-type protein comprises a polypeptide having the amino acid sequence depicted in SEQ ID NO: 16. The invention is further intended to include variants of the receptor subtypes of the invention. For example, a variant of a hmGluR subtype of the invention is a functional or immunological equivalent of said subtype. A functional equivalent is a protein, particularly a human protein, displaying a physiological profile essentially identical to the profile characteristic of said particular subtype. The physiological profile in vitro and in vivo includes receptor effector function, electro physiological and pharmacological properties, e.g. selective interaction with agonists or antagonists. Exemplary functional equivalents may be splice variants encoded by mRNA generated by alternative splicing of a primary transcript, amino acid mutants and glycosylation variants. An immunological equivalent of a particular hmGluR subtype is a protein or peptide capable of generating antibodies specific for said subtype. Portions of the extracellular domain of the receptor, e.g. peptides consisting of at least 6 to 8 amino acids, particularly 20 amino acids, are considered particularly useful immunological equivalents. Further variants included herein are membrane-bound and soluble fragments and covalent or aggregative conjugates with other chemical moieties, these variants displaying one or more receptor functions, such as ligand binding or signal transduction. Exemplary fragments of hmGluR subtypes of the invention are the polypeptides having the amino acid sequences set forth in SEQ ID NOs: 4, 6, 8, 10 and 16, respectively. The fragments of the invention are obtainable from a natural source, by chemical synthesis or by recombinant techniques. Due to their capability of competing with the endogenous counterpart of a hmGluR subtype of the invention for its endogenous ligand, fragments, or derivatives thereof, comprising the ligand binding domain are envisaged as therapeutic agents. Covalent derivatives include for example aliphatic esters or amides of a receptor carboxyl group, O-acyl derivatives of hydroxyl group containing residues and N-acyl derivatives of amino group containing residues. Such derivatives can be prepared by linkage of functionalities to readable groups which are found in the side chains and at the N- and C-terminus of the receptor protein. The protein of the invention can also be labeled with a detectable group, for example radiolabeled, covalently bound to rare earth chelates or conjugated to a fluorescent moiety. Further derivatives are covalent conjugates of a protein of the invention with another protein or peptide (fusion proteins). Examples are fusion proteins comprising different portions of different glutamate receptors. Such fusion proteins may be useful for changing the coupling to G-proteins and/or improving the sensitivity of a functional assay. For example, in such fusion proteins or chimeric receptors, the intracellular domains of a subtype of the invention may be replaced with the corresponding domains of another mGluR subtype, particularly another hmGluR subtype, e.g. a hmGLuR subtype belonging to another subfamily. Particularly suitable for the construction of such a chimeric receptor are the intracellular domains of a receptor which activates the phospholipase C/Ca 2+ signaling pathway, e.g. mGluRl (Masu et al, Nature 349, 760-765) or mGluR5. An intracellular domain suitable for such an exchange is e.g. the second intracellular loop, also referred to as i2 (Pin et al., EMBO J. 13, 342-348 (1994)). Thus it is possible to analyze the interaction of a test compound with a ligand binding domain of a receptor of the invention using an assay for calcium ions. The chimeric receptor according to the invention can be synthesized by recombinant techniques or agents known in the art as being suitable for crosslinking proteins. Aggregative derivatives are e.g. adsorption complexes with cell membranes. In another embodiment, the present invention relates to a composition of matter comprising a hmGluR subtype of the invention. The proteins of the invention are useful e.g. as immunogens, in drug screening assays, as reagents for immunoassays and in purification methods, such as for affinity purification of a binding ligand. A protein of the invention is obtainable from a natural source, e.g. by isolation from brain tissue, by chemical synthesis or by recombinant techniques. The invention further provides a method for preparing a hmGluR subtype of the invention characterized in that suitable host cells producing a receptor subtype of the invention are multiplied in vitro or in vivo. Preferably, the host cells are transformed (transfected) with a hybrid vector comprising an expression cassette comprising a promoter and a DNA sequence coding for said subtype which DNA is controlled by said promoter. Subsequently, the hmGluR subtype of the invention may be recovered. Recovery comprises e.g. isolating the subtype of the invention from the host cells or isolating the host cells comprising the subtype, e.g. from the culture broth. Particularly preferred is a method for preparation of a functionally active receptor. HmGluR muteins may be produced from a DNA encoding a hmGluR protein of the invention which DNA has been subjected to in vitro mutagenesis resulting e.g. in an addition, exchange and/or deletion of one or more amino acids. For example, substitutional, deletional and insertional variants of a hmGluR subtype of the invention are prepared by recombinant methods and screened for immuno-crossreactivity with the native forms of the hmGluR. A protein of the invention may also be derivatized in vitro according to conventional methods known in the art. Suitable host cells include eukaryotic cells, e.g. animal cells, plant cells and fungi, and prokaryotic cells, such as gram-positive and gram-negative bacteria, e.g. E. coli. Preferred eukaryotic host cells are of amphibian or mammalian origin. As used herein, in vitro means ex vivo, thus including e.g. cell culture and tissue culture conditions. This invention further covers a nucleic acid (DNA, RNA) comprising a purified, preferably recombinant, nucleic acid (DNA, RNA) coding for a subtype of the invention, or a fragment of such a nucleic acid. In addition to being useful for the production of the above recombinant hmGluR proteins, these nucleic acid are useful as probes, thus readily enabling those skilled in the art to identify an άV or isolate nucleic acid encoding a hmGluR protein of the invention. The nucleic acid may be unlabeled or labeled with a detectable moiety. Furthermore, nucleic acid according to the invention is useful e.g. in a method for determining the presence of hmGluR, said method comprising hybridizing the DNA (or RNA) encoding (or complementary to) hmGluR to test sample nucleic acid and to determine the presence of hmGluR. Purified hmGluR encoding nucleic acid of the invention includes nucleic acid that is free from at least one contaminant nucleic acid with which it is ordinarily associated in the natural source of hmGluR nucleic acid. Purified nucleic acids thus is present in other than in the form or setting in which it is found in nature. However, purified hmGluR nucleic acid embraces hmGluR nucleic acid in ordinarily hmGluR expressing cells where the nucleic acid is in a chromosomal location different from that of natural cells or is otherwise flanked by a different DNA sequence than that found in nature. In particular, the invention provides a purified or isolated DNA molecule encoding a hmGluR subtype of the invention, or a fragment of such DNA. By definition, such a DNA comprises a coding single DNA, a double stranded DNA consisting of said coding DNA and complementary DNA thereto, or this complementary (single stranded) DNA itself. Preferred is a DNA coding for the above captioned preferred hmGluR subtypes, or a fragment thereof. Furthermore, the invention relates to a DNA comprising such a DNA. More specifically, preferred is a DNA coding for a hmGluR4 subtype or a portion thereof, particularly a DNA encoding the hmGluR4 subtype having the amino acid sequence set forth in SEQ ID NO:2, e.g. the DNA with the nucleotide sequence set forth in SEQ ID NOJ. An exemplary DNA fragment coding for a portion of hmGluR4 is the hmGluR4- encoding portion of cDNA cmR20 as described in the Examples. Equally preferred is a DNA encoding a hmGluR7 subtype, particularly a DNA encoding any of the hmGluR7 subtypes having the amino acid sequences set forth in SEQ ID NOs: 12 and 14, respectively, e.g. the DNAs with the nucleotide sequences set forth in SEQ ID NOs: 11 and 13, respectively. The invention further provides a DNA fragment encoding a portion of a hmGluR7 subtype, particularly the hmGluR7 subtypes identified as preferred above. Exemplary hmGluR7 DNA fragments include the hmGluR7 -encoding portions of cDNAs cmR2, cmR3, cmR5 and CR7PCR1, as described in the Examples, or a DNA fragment which encodes substantially the same amino acid sequence as that encoded by the hmGluR7-encoding portion of plasmid cmR2 deposited with the DSM on September 13, 1993, under accession number DSM 8550. These DNAs encode portions of putative splice variants of the hmGluR7 subtype described herein. Also preferred is a DNA encoding a hmGluRό subtype or a portion thereof, particularly a DNA encoding the portion of the hmGluRό subtype, the amino acid sequence of which is depicted in SEQ ID NO: 16, or a DNA which encodes substantially the same amino acid sequence as that encoded by the hmGluRό-encoding portion of plasmid cmRl deposited with the DSM on September 13, 1993, under accession number DSM 8549. An exemplary DNA sequence is set forth in SEQ ID NO: 15. The nucleic acid sequences provided herein may be employed to identify DNAs encoding further hmGluR subtypes. For example, nucleic acid sequences of the invention may be used for identifying DNAs encoding further hmGluR subtypes belonging to the subfamily comprising hmGluR 4. A method for identifying such DNA comprises contacting human DNA with a nucleic acid probe described above and identifying DNA(s) which hybridize to that probe. Exemplary nucleic acids of the invention can alternatively be characterized as those nucleic acids which encode a hmGluR subtype of the invention and hybridize to a DNA sequence set forth in SEQ ID NOs. 1, 3, 5, 7, 9, 11, 13 or 15, or a selected portion (fragment) of said DNA sequence. For example, selected fragments useful for hybridization are the protein-encoding portions of said DNAs. Preferred are such DNAs encoding a hmGluR of the invention which hybridize under high-stringency conditions to the above-mentioned DNAs. Stringency of hybridization refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (T m ) of the hybrid which decreases approximately 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of higher stringency, followed by washes of varying stringency. As used herein, high stringency refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 1 M Na + at 65-68 °C. High stringency conditions can be provided, for example, by hybridization in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulfate), OJ Na + pyrophosphate and OJ mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridization, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridization temperature in 0.2- OJx SSC, OJ % SDS. Moderate stringency refers to conditions equivalent to hybridization in the above described solution but at about 60-62 °C. In that case the final wash is performed at the hybridization temperature in lx SSC, 0J % SDS. Low stringency refers to conditions equivalent to hybridization in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridization temperature in 2x SSC, 0J % SDS. It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhart's solution and SSC are well known to those of skill in the art as are other suitable hybridization buffers (see, e.g. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual (2nd edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, or Ausubel, F. M., et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, USA). Optimal hybridization conditions have to be determined empirically, as the length and the GC content of the probe also play a role. Given the guidance of the present invention, the nucleic acids of the invention are obtainable according to methods well known in the art. The present invention further relates to a process for the preparation of such nucleic acids. For example, a DNA of the invention is obtainable by chemical synthesis, by recombinant DNA technology or by polymerase chain reaction 0?CR). Preparation by recombinant DNA technology may involve screening a suitable cDNA or genomic library. A suitable method for preparing a DNA or of the invention comprises the synthesis of a number of oligonucleotides, their amplification by PCR methods, and their splicing to give the desired DNA sequence. Suitable libraries are commercially available, e.g. the libraries employed in the Examples, or can be prepared from neural or neuronal tissue samples, e.g. hippocampus and cerebellum tissue, cell lines and the like. For individual hmGluR subtypes (and splice variants) of the invention the expression pattern in neural or neuronal tissue may vary. Thus, in order to isolate cDNA encoding a particular subtype (or splice variant), it is advantageous to screen libraries prepared from different suitable tissues or cells. As a screening probe, there may be employed a DNA or RNA comprising substantially the entire coding region of a hmGluR subtype of the invention, or a suitable oligonucleotide probe based on said DNA. A suitable oligonucleotide probe (for screening involving hybridization) is a single stranded DNA or RNA that has a sequence of nucleotides that includes at least 14 contiguous bases that are the same as (or complementary to) any 14 or more contiguous bases set forth in any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13 and 15. The probe may be labeled with a suitable chemical moiety for ready detection. The nucleic acid sequences selected as probes should be of sufficient length and sufficiently unambiguous so that false positive results are minimized. Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode ligand binding sites, and the like. For example, either the full-length cDNA clones disclosed herein or fragments thereof can be used as probes. Preferably, nucleic acid probes of the invention are labeled with suitable label means for ready detection upon hybridization. For example, a suitable label means is a radiolabel. The preferred method of labelling a DNA fragment is by incorporating 32 P-labelled α-dATP with the Klenow fragment of DNA polymerase in a random priming reaction, as is well known in the art. Oligonucleotides are usually end-labeled with 32 P-labeled γ-ATP and polynucleotide kinase. However, other methods (e.g. non-radioactive) may also be used to label the fragment or oligonucleotide, including e.g. enzyme labelling and biotinylation. After screening the library, e.g. with a portion of DNA including substantially the entire hmGluR-encoding sequence or a suitable oligonucleotide based on a portion of said DNA, positive clones are identified by detecting a hybridization signal; the identified clones are characterized by restriction enzyme mapping and/or DNA sequence analysis, and then examined, e.g. by comparison with the sequences set forth herein, to ascertain whether they include DNA encoding a complete hmGluR (i.e., if they include translation initiation and termination codons). If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If the library is genomic, then the overlapping clones may include exons and introns. If the library is a cDNA library, then the overlapping clones will include an open reading frame. In both instances, complete clones may be identified by comparison with the DNAs and deduced amino acid sequences provided herein. Furthermore, in order to detect any abnormality of an endogenous hmGluR subtype of the invention genetic screening may be carried out using the nucleotide sequences of the invention as hybridization probes. Also, based on the nucleic acid sequences provided herein antisense-type therapeutic agents may be designed. It is envisaged that the nucleic acid of the invention can be readily modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof. Such modified sequences can be used to produce a mutant hmGluR subtype which differs from the receptor subtypes found in nature. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation must not place sequences out of reading frames and preferably will not create complementary regions that could hybridize to produce secondary mRNA structures such as loops or hairpins. The cDNA or genomic DNA encoding native or mutant hmGluR of the invention can be incorporated into vectors for further manipulation. Furthermore, the invention concerns a recombinant DNA which is a hybrid vector comprising at least one of the above mentioned DNAs. The hybrid vectors of the invention comprise an origin of replication or an autonomously replicating sequence, one or more dominant marker sequences and, optionally, expression control sequences, signal sequences and additional restriction sites. Preferably, the hybrid vector of the invention comprises an above described nucleic acid insert operably linked to an expression control sequence, in particular those described hereinafter. Vectors typically perform two functions in collaboration with compatible host cells. One function is to facilitate the cloning of the nucleic acid that encodes the hmGluR subtype of the invention, i.e. to produce usable quantities of the nucleic acid (cloning vectors). The other function is to provide for replication and expression of the gene constructs in a suitable host, either by maintenance as an extrachromosomal element or by integration into the host chromosome (expression vectors). A cloning vector comprises the DNAs as described above, an origin of replication or an autonomously replicating sequence, selectable marker sequences, and optionally, signal sequences and additional restriction sites. An expression vector additionally comprises expression control sequences essential for the transcription and translation of the DNA of the invention. Thus an expression vector refers to a recombinant DNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into a suitable host cell, results in expression of the cloned DNA. Suitable expression vectors are well known in the art and include those that are replicable in eukaryotic and/or prokaryotic cells. Most expression vectors are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in E. coli and then the same vector is transfected into yeast or mammalian cells even though it is not capable of replicating independently of the host cell chromosome. DNA may also be amplified by insertion into the host genome. However, the recovery of genomic DNA encoding hmGluR is more complex than that of exogenously replicated vector because restriction enzyme digestion is required to excise hmGluR DNA. DNA can be amplified by PCR and be directly transfected into the host cells without any replication component. Advantageously, expression and cloning vector contain a selection gene also referred to as selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotro phic deficiencies. or supply critical nutrients not available from complex media. Since the amplification of the vectors is conveniently done in E. coli, an E. coli genetic marker and an E. coli origin of replication are advantageously included. These can be obtained from E. coli plasmids, such as pBR322, Bluescript vector or a pUC plasmid. Suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up hmGluR nucleic acid, such as dihydrofolate reductase (DHFR, methotrexate resistance), thymidine kinase, or genes confering resistance to G418 or hygromycin. The mammalian cell transfectants are placed under selection pressure which only those transfectants are uniquely adapted to survive which have taken up and are expressing the marker. Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to hmGluR nucleic acid. Such promoter may be inducible or constitutive. The promoters are operably linked to DNA encoding hmGluR by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native hmGluR promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of hmGluR DNA. However, heterologous promoters are preferred, because they generally allow for greater transcription and higher yields of expressed hmGluR as compared to native hmGluR promoter. Promoters suitable for use with prokaryotic hosts include, for example, the β-lactamase and lactose promoter systems, alkaline phosphatase, a tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Their nucleotide sequences have been published, thereby enabling the skilled worker operably to ligate them to DNA encoding hmGluR, using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems will also generally contain a Shine-Delgarno sequence operably linked to the DNA encoding hmGluR. HmGluR gene transcription from vectors in mammalian host cells may be controlled by promoters compatible with the host cell systems, e.g. promoters derived from the genomes of viruses. Suitable plasmids for expression of a hmGluR subtype of the invention in eukaryotic host cells, particularly mammalian cells, are e.g. cytomegalovirus (CMV) promoter-containing vectors, RSV promoter-containing vectors and SV40 promoter-containing vectors and MMTV LTR promoter-containing vectors. Depending on the nature of their regulation, promoters may be constitutive or regulatable by experimental conditions. Transcription of a DNA encoding a hmGluR subtype according to the invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. The various DNA segments of the vector DNA are operatively linked, i.e. they are contiguous and placed into a functional relationship to each other. Construction of vectors according to the invention employs conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a manner known in the art. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing hmGluR expression and function are known to those skilled in the art. Gene presence, amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), in situ hybridization, using an appropriately labelled probe based on a sequence provided herein, binding assays, immunodetection and functional assays. Suitable methods include those decribed in detail in the Examples. Those skilled in the art will readily envisage how these methods may be modified, if desired. The invention further provides host cells capable of producing a hmGluR subtype of the invention and including heterologous (foreign) DNA encoding said subtype. The nucleic acids of the invention can be expressed in a wide variety of host cells, e.g. those mentioned above, that are transformed or transfected with an appropriate expression vector. The receptor of the invention (or a portion thereof) may also be expressed as a fusion protein. Recombinant cells can then be cultured under conditions whereby the protein (s) encoded by the DNA of the invention is (are) expressed. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-prositive organisms, such as E. coli, e.g. E. coli K-12 strains, DH5α and HB 101, or Bacilli. Further host cells suitable for hmGluR encoding vectors include eukaryotic microbes such as filamentous fungi or yeast, e.g. Saccharomyces cerevisiae. Higher eukaryotic cells include insect, amphebian and vertebrate cells, particularly mammalian cells, e.g. neuroblastoma cell lines or fibroblast derived cell lines. Examples of preferred mammalian cell lines are e.g. HEK 293 cells, CHO cells, CV1 cells, BHK cells, L cells, LLCPK-1 cells, GH3 cells, L cells and COS cells. In recent years propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. The host cells referred to in this application comprise cells in in vitro culture as well as cells that are within a host animal. Suitable host cells for expression of an active recombinant hmGluR of the invention advantageously express endogenous or recombinant G-proteins. Preferred are cells producing little, if any, endogenous metabotropic glutamate receptor. DNA may be stably incorporated into the cells or may be transiently expressed according to conventional methods. Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene, and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, mammalian cells are transfected with a reporter gene to monitor transfection efficiency. To produce such stably or transiently transfected cells, the cells should be transfected with a sufficient amount of hmGluR-encoding nucleic acid to form hmGluR of the invention. The precise amounts of DNA encoding hmGluR of the invention may be empirically determined and optimized for a particular cell and assay. A DNA of the invention may also be expressed in non-human transgenic animals, particularly transgenic warm-blooded animals. Methods for producing transgenic animals, including mice, rats, rabbits, sheep and pigs, are known in the art and are disclosed, for example by Hammer et al. (Nature 315, 680-683, 1985). An expression unit including a DNA of the invention coding for a hmGluR together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs. Introduction may be achieved, e.g. by microinjection. Integration of the injected DNA is detected, e.g. by blot analysis of DNA from suitable tissue samples. It is preferred that the introduced DNA be incorporated into the germ line of the animal so that it is passed to the animal's progeny. Preferably, a transgenic animal is developped by targeting a mutation to disrupt a hmGluR sequence. Such an animal is useful e.g. for studying the role of a metabotropic receptor in metabolism . Furthermore, a knock-out animal may be developed by introducing a mutation in the hmGluR sequence, thereby generating an animal which does not express the functional hmGluR gene anymore. Such knock-out animal is useful e.g. for studying the role of metabotropic receptor in metabolism, methods for producing knock-out mice are known in the art. Host cells are transfected or transformed with the above-captioned expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Heterologous DNA may be introduced into host cells by any method known in the art, such as transfection with a vector encoding a heterologous DNA by the calcium phosphate coprecipitation technique, by electroporation or by lipofectin-mediated. Numerous methods of transfection are known to the skilled worker in the field. Successful transfection is generally recognized when any indication of the operation of this vector occurs in the host cell. Transformation is achieved using standard techniques appropriate to the particular host cells used. Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are well known in the art (see, e.g. Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press). Transfected or transformed cells are cultured using media and culturing methods known in the art, preferably under conditions, whereby hmGluR encoded by the DNA is expressed. The composition of suitable media is known to those in the art, so that they can be readily prepared. Suitable culturing media are also commercially available. While the DNA provided herein may be expressed in any suitable host cell, e.g. those referred to above, preferred for expression of DNA encoding functional hmGluR are eukaryotic expression systems, particularly mammalian expression systems, including commercially available systems and other systems known to those of skill in the art. Human mGluR DNA of the invention is ligated into a vector, and introduced into suitable host cells to produce transformed cell lines that express a particular hmGluR subtype of the invention, or specific combinations of subtypes. The resulting cell line can then be produced in amounts sufficient for reproducible qualitative and quantitative analysis of the effects of a receptor agonist, antagonist or allosteric modulator. Additionally, mRNA may be produced by in vitro transcription of a DNA encoding a subtype of the invention. This mRNA may be injected into Xenopus oocytes where the mRNA directs the synthesis of the active receptor subtype. Alternatively, the subtype-encoding DNA can be directly injected into oocytes. The transfected mammalian cells or injected oocytes may then be employed in an drug screening assay provided hereinafter. Such drugs are useful in diseases associated with pathogenesis of a hmGluR subtype of the invention. Such diseases include diseases resulting from excessive action of glutamate preferentially mediated by hmGluRs, such as stroke, epilepsy and chronic neurogenerative diseases. Particularly useful for assessing the specific interaction of compounds with specific hmGluR subtypes are stably transfected cell lines expressing a hmGluR of the invention. Thus host cells expressing hmGluR of the invention are useful for drug screening and it is a further object of the present invention to provide a method for identifying a compound or signal which modulates the activity of hmGluR, said method comprising exposing cells containing heterologous DNA encoding hmGluR of the invention, wherein said cells produce functional hmGluR, to at least one compound or signal whose ability to modulate the activity of said hmGluR is sought to be determined, and thereafter monitoring said cells for changes caused by said modulation. Such an assay enables the identification of agonists, antagonists and allosteric modulators of a hmGluR of the invention. In a further aspect, the invention relates to an assay for identifying compounds which modulate the activity of a hmGluR subtype of the invention, said assay comprising: - contacting cells expressing an active hmGluR subtype of the invention and containing heterologous DNA encoding said hmGluR subtype with at least one compound to be tested for its ability to modulate the activity of said receptor, and - analysing cells for a difference in second messenger level or receptor activity. In particular, the invention covers an assay for identifying compounds which modulate the activity of a hmGluR subtype of the invention, said assay comprising: - contacting cells expressing active hmGluR of the invention and containing heterologous DNA encoding said hmGluR subtype with at least one compound to be tested for its ability to modulate the activity of said receptor, and - monitoring said cells for a resulting change in second messenger activity. The result obtained in the assay is compared to an assay suitable as a negative control. Assay methods generally require comparison to various controls. A change in receptor activity or in second messenger level is said to be induced by a test compound if such an effect does not occur in the absence of the test compound. An effect of a test compound on a receptor subtype of the invention is said to be mediated by said receptor if this effect is not observed in cells not expressing the receptor. As used herein, a compound or signal that modulates the activity of a hmGluR of the invention refers to a compound or signal that alters the response pathway mediated by said hmGluR within a cell (as compared to the absence of said hmGluR). A response pathway is activated by an extracellular stimulus, resulting in a change in second messenger concentration or enzyme activity, or resulting in a change of the activity of a membrane-bound protein, such as a receptor or ion channel. A variety of response pathways may be utilized, including for example, the adenylate cyclase response pathway, the phospholipase C/intracellular calcium ion response pathway or coupling to an ion channel. Assays to determine adenylate cyclase activity are well known in the art, and include e.g. the assay disclosed by Nakajima et al., J. Biol. Chem. 267, 2437-2442 (1992)) Thus cells expressing hmGluR of the invention may be employed for the identification of compounds, particularly low molecular weight molecules capable of acting as glutamate agonists or antagonists. Preferred are low molecular weight molecules of less than 1,000 Dalton. Within the context of the present invention, an agonist is understood to refer to a molecule that is capable of interacting with a receptor, thus mimicking the action of L-glutamate. In particular, a glutamate agonist is characterized by its ability to interact with a hmGluR of the invention, and thereby increasing or decreasing the stimulation of a response pathway within a cell. For example, an agonist increases or decreases a measurable parameter within the host cell, such as the concentration of a second messenger, as does the natural ligand increase or decrease said parameter. For example, in a suitable test system, wherein hmGluR of the invention is negatively coupled to adenylate cyclase, e.g. CHO or BHK cells expressing a hmGluR of the invention, such an agonist is capable of modulating the function of said hmGluR such that the intracellular concentration of cAMP is decreased. By contrast, in situations where it is desirable to tone down the activity of hmGluR, antagonizing molecules are useful. Within the context of the present invention, an antagonist is understood to refer to a molecule that is capable of interacting with a receptor or with L-glutamate, but which does not stimulate a response pathway within a cell. In particular, glutamate antagonists are generally identified by their ability to interact with a hmGluR of the invention, and thereby reduce the ability of the natural ligand to stimule a response pathway within a cell, e.g. by interfering with the binding of L-glutamate to a hmGluR of the invention or by inhibiting other cellular functions required for the activity of hmGluR. For example, in a suitable assay, e.g. an assay involving CHO or BHK cells expressing a hmGluR subtype of the invention, a glutamate antagonist is capable of modulating the activity of a hmGluR of the invention such that the ability of the natural ligand to decrease the intracellular cAMP concentration is weakened. Yet another alternative to achieve an antagonistic effect is to rely on overexpression of antisense hmGluR RNA. Preferred is an agonist or antagonist selectively acting on a receptor of the hmGluR4 subfamily, e.g. hmGluR4, hmGluRό or hmGluR7. Particularly useful is an agonist or antagonist specifically modulating the activity of a particular hmGluR subtype without affecting the activity of any other subtype. An allosteric modulator of a hmGluR of the invention interacts with the receptor protein at another site than L-glutamate, thus acting as agonist or antagonist. Therefore, the screening assays decribed herein are also useful for detecting an allosteric modulator of a receptor of the invention. For example, an allosteric modulator acting as agonist may enhance the specific interaction between a hmGluR of the invention and L-glutamate. If an allosteric modulator acts as an antagonist, it may e.g. interact with the receptor protein in such a way that binding of the agonist is functionally less effective. An in vitro assay for a glutamate agonist or antagonist may require that a hmGluR of the invention is produced in sufficient amounts in a functional form using recombinant DNA methods. An assay is then designed to measure a functional property of the hmGluR protein, e.g. interaction with a glutamatergic ligand. Production of a hmGluR of the invention is regarded as occurring in sufficient amounts, if activity of said receptor results in a measurable response. For example, mammalian cells, e.g. HEK293 cells, L cells, CHO-Kl cells, LLCPK-1 cells or GH3 cells (available e.g. from the American Tissue Type Culture Collection) are adapted to grow in a glutamate reduced, preferably a glutamate free, medium. A hmGluR expression plasmid, e.g. a plasmid described in the Examples, is transiently transfected into the cells, e.g. by calcium-phosphate precipitation (Ausubel, F. M., et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, USA). Cell lines stably expressing a hmGluR of the invention may be generated e.g. by lipofectin-mediated transfection with hmGluR expression plasmids and a plasmid comprising a selectable marker gene, e.g. pSV2-Neo (Southern and Berg, J. Mol. Appl. Genet. 1, 327-341 (1982)), a plasmid vector encoding the G-418 resistence gene. Cells surviving the selection are isolated and grown in the selection medium. Resistant clonal cell lines are analyzed, e.g. for immunoreactivity with subtype-specific hmGluR antibodies or by assays for hmGluR functional responses following agonist addition. Cells producing the desired hmGluR subtype are used in a method for detecting compounds binding to a hmGluR of the invention or in a method for identifying a glutamate agonist or antagonist. In a further embodiment, the invention provides a method for identifying compounds binding to a hmGluR subtype, said method comprising employing a hmGluR subtype of the invention in a competitive binding assay. The principle underlying a competitive binding assay is generally kown in the art. Briefly, binding assays according to the invention are performed by allowing the compound to be tested for its hmGluR binding capability to compete with a known, suitably labeled, glutamatergic ligand for the binding site at the hmGluR target molecule. A suitably labeled ligand is e.g. a radioactively labeled ligand, such as [ 3 H]glutamate, or a ligand which can be detected by its optical properties, such as absorbance or fluorescence. After removing unbound ligand and test compound the amount of labeled ligand bound to hmGluR is measured. If the amount of labeled ligand is reduced in the presence of the test compound this compound is said to be bound to the target molecule. A competitive binding assay may be performed e.g. with 95/08627 - 20 - transformed or transfected host cells expressing a hmGluR of the invention or a membraneous cellular fraction comprising a hmGluR of the invention. Compound bound to the target hmGluR may modulate the functional properties of hmGluR and may thereby be identified as a glutamate agonist or antagonist in a functional assay. Functional assays are used to detect a change in the functional activity of a hmGluR of the invention, i.e. to detect a functional response, e.g. as a result of the interaction of the compound to be tested with said hmGluR. A functional response is e.g. a change (difference) in the concentration of a relevant second messenger, or a change in the activity of another membrane-bound protein influenced by the receptor of the invention within cells expressing a functional hmGluR of the invention (as compared to a negative control). Those of skill in the art can readily identify an assay suitable for detecting a change in the level of an intracellular second messenger indicative of the expression of an active hmGluR (functional assay). Examples include cAMP assays (see, e.g. Nakajima et al., J. Biol. Chem. 267, 2437-2442 (1992), cGMP assays (see, e.g. Steiner et al., J. Biol. Chem. 247, 1106-1113 (1972)), phosphatidyl inositol (PI) turnover assays (Nakajima et al., J. Biol. Chem. 267, 2437-2442 (1992)), calcium ion flux assays (Ito et al., J. Neurochem. 56, 531-540 (1991)), arachidonic acid release assays (see, e.g. Felder et al., J. Biol. Chem. 264, 20356-20362 (1989)), and the like. More specifically, according to the invention a method for detecting a glutamate agonist comprises the steps of (a) exposing a compound to a hmGluR subtype of the invention coupled to a response pathway, under conditions and for a time sufficient to allow interaction of the compound with the receptor and an associated response through the pathway, and (b) detecting an increase or decrease in the stimulation of the response pathway resulting from the interaction of the compound with the hmGluR subtype, relative to the absence of the tested compound and therefrom determining the presence of a glutamate agonist. A method for identifying a glutamate antagonist comprises the steps of (a) exposing a compound in the presence of a known glutamate agonist to a hmGluR subtype of the invention coupled to a response pathway, under conditions and for a time sufficient to allow interaction of the agonist with the receptor and an associated response through the pathway, and (b) detecting an inhibition of the stimulation of the response pathway by the agonist resulting from the interaction of the compound with the hmGluR subtype, relative to the stimulation of the response pathway by the glutamate agonist alone and therefrom determining the presence of a glutamate antagonist. Inhibition may be detected, e.g. if the test compound competes with the glutamate agonist for the hmGluR of the invention. Compounds which may be screened utilizing such method are e.g. blocking antibodies specifically binding to the hmGluR subtype. Furthermore, such an assay is useful for the screening for compounds interacting with L-glutamate, e.g. soluble hmGluR fragments comprising part or all of the ligand binding domain. Preferentially, interaction of an agonist or antagonist with a hmGluR of the invention denotes binding of the agonist or antagonist to said hmGluR. As employed herein, conditions and times sufficient for interaction of a glutamate agonist or antagonist candidate to the receptor will vary with the source of the receptor, however, conditions generally suitable for binding occur between about 4°C and about 40°C, preferably between about 4°C and about 37°C, in a buffer solution between 0 and 2 M NaCl, preferably between 0 and 0.9 M NaCl, with OJ M NaCl being particularly preferred, and within a pH range of between 5 and 9, preferably between 6.5 and 8. Sufficient time for the binding and response will generally be between about 1 ms and about 24 h after exposure. Within one embodiment of the present invention, the response pathway is a membrane-bound adenylate cyclase pathway, and, for an agonist, the step of detecting comprises measuring a reduction or increase, preferably a reduction, in cAMP production by the membrane-bound adenylate cyclase response pathway, relative to the cAMP production in the relevant control setup. For the purpose of the present invention, it is preferred that the reduction or increase in cAMP production be equivalent or greater than the reduction or increase induced by L-glutamate applied at a concentration corresponding to its IC 50 concentration. For an antagonist, the step of detecting comprises measuring in the presence of the antagonist a smaller L-glutamate induced decrease or increase in cAMP production by the membrane-bound adenylate cyclase response pathway, as compared to the cAMP production in the absence of the antagonist. The measurement of cAMP may be performed after cell destruction or by a cAMP sensitive molecular probe loaded into the cell, such as a fluorescent dye, which changes its properties, e.g. its fluorescent properties, upon binding of cAMP. Cyclic AMP production may be measured using methods well known in the art, including for instance, methods described by Nakajima et al., supra, or using commercially available kits, e.g. kits comprising radiolabeled cAMP, e.g. [ 125 I]cAMP or [ 3 H]cAMP. Exemplary kits are the Scintillation Proximity Assay Kit by Amersham, which measures the production of c AMP by competition of iodinated-cAMP with cAMP antibodies, or the Cyclic AMP [ 3 H] Assay Kit by Amersham. In assay systems using cells expressing receptor subtypes that are negatively coupled to the adenylate cyclase pathway, i.e. which cause a decrease in cAMP upon stimulation and an increase in c AMP upon reduction of stimulation, it is preferred to expose the cells to a compound which reversibly or irreversibly stimulates the adenylate cyclase, e.g. forskolin, or which is a phosphodiesterase inhibitor, such as isobutylmethylxanthine (IB MX), prior to addition of the (potential) receptor agonist or antagonist. Within another embodiment of the invention, the response pathway is the PI hydrolysis/ Ca 2+ mobilization pathway. Such an assay for determining the specific interaction of a test compound with a hmGluR subtype of the invention may be functionally linked to changes in the intracellular calcium ion (Ca 2+ ) concentration. Several methods for determining a change in the intracellular concentration of Ca 2+ are known in the art, e.g. a method involving a calcium ion sensitive fluoroscent dye, such as fura-2 (see Grynkiewisz et al., J. Biol. Chem. 260, 3440-3450, 1985), fluo-3 or Indo-1, such as the calcium fluor QuinZ method describe by Charest et al. (J. Biol. Chem. 259, 8679-8773 (1993)), or the aequorin photoprotein method described by Nakajima-Shimada (Proc. Natl Acad. Sci. USA 88, 6878-6882 (1991)). In one embodiment of the invention, intracellular calcium ion concentration is measured by microfluoremetry in recombinant cells loaded with calcium sensitive fluorescent dyes fluo-3 or fura-2. These measurements may be performed using cells grown in a coverslip allowing the use of an inverted microscope and video-imaging technologies or a fluorescence photometer to measure calcium concentrations at the single cell level. For both approaches, cells transformed with a hmGluR expressing plasmid have to be loaded with the calcium indicator. To this end, the growth medium is removed from the cells and replaced with a solution containing fura-2 or fluo-3. The cells are used for calcium measurements preferentially during the following 8h. The microfluorometry follows standard procedures. Ca 2+ signals resulting from functional interaction of compounds with the target molecule can be transient if the compound is applied for a limited time period, e.g. via a perfusion system. Using transient application several measurements can be made with the same cells allowing for internal controls and high numbers of compounds tested. Functional coupling of a hmGluR of the invention to Ca 2+ signaling may be achieved, e.g. in CHO cells, by various methods: (i) coexpression of a recombinant hmGluR of the invention and a recombinant voltage-gated cation channel, activity of which is functionally linked to the activity of the hmGluR; (ii) expression of a chimeric hmGluR receptor, which directly stimulates the PI/Ca 2+ pathway; (iii) coexpression of a recombinant hmGluR of the invention with a recombinant Ca 2+ -permeable cAMP dependent cation channel. In other expression systems functional coupling of a hmGluR to Ca 2+ signalling may be achieved by transfection of a hmGluR of the invention if these cells naturally express (i) voltage gated Ca channels, activity of which is functionally linked to activity of mGluRs or (ii) Ca 2+ -permeable cAMP dependent ion channels. For example, GH3 cells which naturally express voltage-gated Ca channels, directly allow application of Ca 2+ assays to test for hmGluR functional activity by cotransfection of hmGluRs. Further cell-based screening assays can be designed e.g. by constructing cell lines in which the expression of a reporter protein, i.e. an easily assayable protein, such as β-galactosidase, chloramphenicol acetyltransferase (CAT) or luciferase, is dependent on the function of a hmGluR of the invention. For example, a DNA construct comprising a cAMP response element is operably linked to a DNA encoding luciferase. The resulting DNA construct comprising the enzyme DNA is stably transfected into a host cell. The host cell is then transfected with a second DNA construct containing a first DNA segment encoding a hmGluR of the invention operably linked to additional DNA segments necessary for the expression of the receptor. For example, if binding of a test compound to the hmGluR of the invention results in elevated cAMP levels, the expression of luciferase is induced or decreased, depending on the promoter chosen. The luciferase is exposed to luciferin, and the photons emitted during oxidation of luciferin by the luciferase is measured. The drug screening assays provided herein will enable identification and design of receptor subtype-specific compounds, particularly ligands binding to the receptor protein, eventually leading to the development of a disease-specific drug. If designed for a very specific interaction with only one particular hmGluR subtype (or a predetermined selection of hmGluR subtypes) such a drug is most likely to exhibit fewer unwanted side effects than a drug identified by screening with cells that express a(n) (unknown) variety of receptor subtypes. Also, testing of a single receptor subtype of the invention or specific combinations of different receptor subtypes with a variety of potential agonists or antagonists provides additional information with respect to the function and activity of the individual subtypes and should lead to the identification and design of compounds that are capable of very specific interaction with one or more receptor subtypes. In another embodiment the invention provides polyclonal and monoclonal antibodies generated against a hmGluR subtype of the invention. Such antibodies may useful e.g. for immunoassays including immunohistochemistry as well as diagnostic and therapeutic applications. For example, antibodies specific for the extracellular domain, or portions thereof, of a particular hmGluR subtype can be applied for blocking the endogenous hmGluR subtype. The antibodies of the invention can be prepared according to methods well known in the art using as antigen a hmGluR subtype of the invention, a fragment thereof or a cell expressing said subtype or fragment. The antigen may represent the active or inactive form of the receptor of the invention. Antibodies may be capable of distinguishing between the active or inactive form. Factors to consider in selecting subtype fragments as antigens (either as synthetic peptide or as fusion protein) include antigenicity, accessibility (i.e. extracellular and cytoplasmic domains) and uniqueness to the particular subtype. Particularly useful are antibodies selectively recognizing and binding to receptor subtypes of the above described subfamily without binding to a subtype of another subfamily and antibodies selectively recognizing and binding to one particular subtype without binding to any other subtype. The antibodies of the invention can be administered to a subject in need thereof employing standard methods. One of skill in the art can readily determine dose forms, treatment regimens etc, depending on the mode of administration employed. The invention particularly relates to the specific embodiments as described in the Examples which serve to illustrate the present invention but should not be construed as a limitation thereof. Abbreviations: hmGluR = human metabotropic glutamate receptor, nt=nucleotide Example 1: cDNA encoding hmGluR4 Human mGluR4 cDNA clones are isolated from human fetal brain and human cerebellum cDNA libraries by low stringency hybridization using a radiolabeled rat mGluR4 probe generated by PCR from rat brain cDNA. 1J Preparation of poly(A) + RNA from rat forebrain Adult male Sprague-Dawley rats are killed by suffocation, their forebrain is removed and immediately frozen in liquid N 2 . Total RNA is isolated using the guanidinium thio- cyanate-procedure (Chomczynski and Sacchi (1987), Anal. Biochem. 162, 156-159). Enrichment of poly(A) + RNA is achieved by affinity chromatography on oligo(dT)- cellulose according to standard procedures (Sambrook, J ., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual (2nd edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA). 1.2 First strand cDNA synthesis for PCR Poly(A) + RNA (mRNA) is reverse-transcribed into DNA by Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT, BRL). 50 μl reactions are set up as follows: 10 μg of rat forebrain poly(A) + RNA in 10 μl sterile H2O are heated to 70° C for 10 min and then quickly chilled on ice. Then, 10 μl 5x reaction buffer (250 mM Tris-HCI pH 8.3, 375 mM KCl, 15 mM MgCl 2 ), 5 μl 0JM dithiothreitol, 5 μl mixed dNTP (lOmM each of dATP, dCTP, dGTP, dTTP, Pharmacia), 1.25 μl oligo-dTi2_i8 (2mg/ml, Pharmacia), 2.5 μl RNAsin (40U/μl, Promega), 12.25 μl sterile H O and 4 μl (200 U/μl) M-MLV RT are added. The reaction is carried out at 37°C for 60 min. 1.3 PCR conditions for generating the rat mGluR4 fragment The oligodeoxynucleotide primers used for PCR are synthesized by the phosphoramidite method. Sequences are listed in Table 1. Table 1 PI : 5'- GTCAAGGCCTCGGGCCGGGA -3' corresponding to bp 1921-1940 of rat mGluR4 cDNA (Tanabe, et al., (1992), Neuron 8, 169-179) P2: 5'- CTAGATGGCATGGTTGGTGTA-3' corresponding to bp 2788-2808 of rat mGluR4 cDNA (Tanabe, et al., (1992), Neuron 8, 169-179) Standard PCR-conditions for a 100 μl reaction mixture are: 30 ng of rat forebrain cDNA, 50 pmol each of primers PI and P2, 200 μmol each of the four deoxynucleoside triphosphates dATP, dCTP, dGTP and dTTP, 10% DMSO in PCR-buffer (10 mM Tris-HCI, pH 8.3, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM β-mercaptoethanol, 0.05% Tween (w/v), 0.05% NP-40 (w/v)), and 0.5 U AmpliTaq Polymerase (Perkin Elmer Cetus). The amplification is performed using the following conditions: 30 sec denaturing at 93° C, 1 min 30 sec annealing at 56°C, and 3 min extension at 72°C, for a total of 40 cycles. Initial denaturation is carried out for 4 min at 94°C. 1.4 Subcloning of the rat mGluR4 PCR fragment Restriction endonuclease digestions, use of modifying enzymes, vector preparation (dephosphorylation, gel purification), ligations, transformation of E. coli, and plasmid DNA preparations are performed according to standard procedures ( Sambrook, et al. (1989), supra). The PCR fragment (888 bp) obtained according to the procedure described in 1.3 is ligated into the Smal site of the Bluescript SK + plasmid (Stratagene, La J olla, USA). The fragment inserted into the Bluescript vector is sequenced from both ends using T7 and T3 primers (Stratagene, La Jolla, USA). 1.5 Preparation of a radiolabeled probe 20-50 ng of the PCR generated rat mGluR4 fragment are gel purified and 32 P-labeled by random priming using a DNA Labeling Kit (Boehringer Mannheim). 1.6 cDNA library screening About lxlO 6 phages from a human fetal brain library (λZAPII, Stratagene, La Jolla, USA), human hippocampus (λZAP, Stratagene, La Jolla, USA), and a human cerebellum cDNA library (λZAP, Stratagene) are screened for hybridization to the rat mGluR4 fragment. Hybridization is performed in 5x SSC, 0.02% (w/v) Ficoll (Type 400), 0.02% (w/v) Polyvinylpyrrolidone, 0.1% (w/v) SDS, 50 μg/ml Herring Testis DNA. Prehybridization is carried out between 30 min to 3 hours at 58°C. Hybridization is carried out at low stringency at 58°C overnight in the same solution containing the 32 P-labeled fragment at a concentration of l-3x IO 5 cpm/ml. Washes are done three times for 20 min each at 58°C in 2x SSC/0J% SDS. Phages hybridizing to the rat mGluR4 probe are purified by a second and third round of screening under the conditions described above. The cDNA inserts harbored by the purified phages are rescued by in vivo excision using the ExAssist/SOLR system (Stratagene, La Jolla, USA). 1.7 Characterization of isolated cDNA clones Several cDNA inserts are characterized by restriction enzyme mapping and DNA sequence analysis. One of these clones, cDNA cmR20 (isolated from human cerebellar library) contains an insert of approximately 3.3 kb. Sequence analysis of cmR20 indicates that it contains almost the complete coding region of human mGluR4 including a translation termination codon (nt 158 to 2739, cf. SEQ ID NO:l) as well as approximately 750 nt of 3' untranslated region. The 5' end including the translational start codon is lacking. 1.8 Isolation of the 5' end of human mGluR4 To complete the coding region of human mGluR4 PCR reactions are carried out using human genomic DNA or first strand cDNA of human brain RNA as a template. The sense primer P3 corresponds to the 5' end of the rat mGluR4 cDNA, the antisense primer P4 to nt 440-459 of the rat mGluR4 cDNA. Table 2 P3: 5'-GCGCTGCAGGCGGCCGCAGGGCCTGCTAGGGCTAGGAGCGGGGC-3- corresponding to nt 11-37 of rat mGluR4 cDNA (Tanabe, et al., (1992), Neuron 8, 169-179) P4: 5'-G( GGAATTCCCTCCGTGCCGTCCTTCTCG-3' corresponding to nt 440-459 of rat mGluR4 cDNA (Tanabe, et al., (1992), Neuron 8, 169-179) Additional sequences are underlined, sites for restriction enzymes are indicated in boldface PCR reactions for a 100 μl reaction mixture are: 400 ng of human genomic DNA, 1 μM of each primer, 2 mM of each deoxynucleoside triphosphate (dATP, dCTP, dGTP and dTTP) in PCR-buffer (lOmM Tris-HCI, pH 8.3, 1.5 mM MgCl 2 , 50 mM KCl, and 2 U AmpliTaq Polymerase. The amplification is performed using the following conditions: 1 min denaturation at 95°C, 1 min annealing at 56°C, and 1 min extension at 72°C, for a total of 32 cycles. Initial denaturation is carried out for 3 min at 94°C. Products of several independent PCRs are digested with restriction enzymes Pstl and EcoRI, gel purified, and ligated into the Pstl EcoRI sites of pBluescript SK (Stratagene). Subcloned fragments of several independent PCRs are analyzed by DNA sequence analysis (cR4PCRl-4). Sequence analysis reveals that clone cR4PCR2 encodes 380 nt of hmGluR4 coding region including the translation initiation codon (nt 1 - 380, cf. SEQ ID NO:l). CR4PCR2 overlaps at the 3' end for 223 nt with cmR20. The complete deduced amino acid sequence of the hmGluR4 protein is set forth in SEQ ID NO:2. Example 2: cDNA clones encoding hmGluR7 Screening of human fetal brain and human cerebellum cDNA libraries by low-stringency hybridization using radiolabeled rat mGluR4 fragment (as described in 1.5 and 1.6) allows the isolation of cDNA clones that identify the human metabotropic glutamate receptor subtype mGluR7. Characterization of cDNA clones by DNA sequence analysis reveals that isolated cDNAs represent at least two apparent splice variants of human mGluR7 mRNA. cDNA cmR2 (isolated from human fetal brain cDNA library) has a size of 3804 nt. Clone cmR2 contains 2604 nt of hmGluR7 coding sequence including a translation termination codon followed by 1200 nt of 3' untranslated sequence (cf. SEQ ID NO:3). cDNA cmR3 (isolated from human hippocampus cDNA library) has a size of 1399 nt (SEQ ID NO:5). cmR3 contains 270 nt of the hmGluR7 3' end coding region including a translation termination stop codon (the deduced amino acid sequence is set forth in SEQ ID NO:6) followed by 1129 nt of 3' untranslated sequence. The sequence of cmR3 is completely contained in cmR2 but differs from cmR2 by deletion of the 92 nucleotides extending from the nt at position 2534 to the nt at position 2625 in SEQ ID NO:3). This apparent splice variant of hmGluR7 generates a different 3' end of the deduced hmGluR7 amino acid sequence. cDNA cmR5 (isolated from human fetal brain cDNA library) has a size of 1588 nt (SEQ ID NO:7). cDNA cmR5 overlaps 1424 nt with cDNA cmR2. It diverges at the 3' end exactly at the position of the 92-nt-insertion deletion of cmR2/cmR3. Additional 164 nt of cmR5 either encode intronic sequences as indicated by presence of a conserved splice donor sequence immediately following the site of cmR5 and cmR2/cmR3 sequence divergence, or represent a third splice variant. The 5' end coding region of hmGluR7 DNA missing in cDNA clones cmR2, cmR3, and cmR5, is isolated by a combination of genomic library screening and PCR techniques. A Lamda-Fix genomic library (Stratagene) is screened with a EcoRI/Smal restriction fragment comprising nt 1-1304 of cDNA cmR2 under high stringency hybridization conditions as described in Sambrook, et al. (1989), supra. Lambda clones hybridizing to the 5' end of cDNA clone cmR2 are purified and analyzed by restriction analyses and DNA sequencing. The complete 5' end of the coding region of human mGluR7 including the ATG translation initiation codon is amplified by PCR from human brain cDNA using primer sequences derived from cloned genomic fragments. The PCR fragments has a size of 557 nt. It is designated as cR7PCRland depicted as SEQ ID NO:9. The deduced amino acid sequence is set forth in SEQ ID NO: 10. CR7PCR1 overlaps at the 3' end with cmR2 for 392 nt. The DNA sequences coding for the complete hmGluR7a and b proteins are set forth in SEQ ID NOs: 11 and 13, respectively. The deduced amino acid sequences are given in SEQ ID NOs: 12 and 14, respectively. Comparison of the deduced amino acid sequences reveals approximately 70 % sequence identity to the hmGluR4 subtype of Example 1. Example 3: cDNA encoding partial hmGluRό A single cDNA clone, cmRl, with an insert of 1.0 kb is isolated from a human hippocampus library by low stringency hybridization using the hmGluR fragment as described above in example 1.5 and 1.6. Approximately 630 nucleotides are homologous to human mGluR4. Additional sequences at the 5' and 3' end of cmRl apparently encode intronic sequences as indicated by the presence of putative splice donor and splice acceptor site sequences. cDNA cmRl identifies a portion of the human metabotropic glutamate receptor subtype hmGluRό (SEQ ID NOs. 15). The deduced amino acid sequence is set forth in SEQ ID NO: 16. The complete coding region of hmGluRό is isolated by screening of cDNA and genomic libraries under high stringency conditions with cDNA cmRl as a probe. Comparison of the deduced amino acid sequences reveals approximately 70% sequence identity to hmGluR4 of Example 1. Example 4: Expression of hmGluR cDNAs in mammalian cells 4.1 Receptor expression plasmids cDNAs encoding the above full-length hmGluR4, hmGluRό, and hmGluR7 proteins are generated from cDNA fragments and ligated into mammalian expression vectors based on constitutive promoters (CMV, SV40, RSV) or inducible promoters. Examples are pBK-CMV (Stratagene), pBK-RSV (Stratagene), pCMV-T7 (Sibia, Inc.) and pICP4 (Novagen, USA). The full-length cDNA encoding the hmGluR4 subtype is incorporated into the mammalian expression vector pBK-CMV by ligating the hmGluR4 5' end fragment (clone CR4PCR2) with cDNA cmR20 at the unique Xhol site that is located at nt 346-351 of the hmGluR4 cDNA. Specifically, plasmid pBK-CMV-hmGluR4 is generated by three- way-ligation of the Notl Xhol fragment of cR4PCR2, the Xhol/Notl fragment of cDNA cmR20 and the Notl digested vector pBK-CMV. Plasmid pCMV-T7-hmGluR4 is generated by three- way-ligation of the Pstl/Xhol fragment of cR4PCR4, the XhoI/EcoRI fragment of cmR20 and the Pstl/EcoRI digested vector pCMV-T7-2. Both expression constructs contain the complete coding region of the hmGluR4 as well as approximately 750 nt of 3' untranslated sequences. Full-length cDNAs representing the two hmGluR7 splice variants, designated hmGluR7a (SEQ ID NO: 12) and hmGluR7b SEQ ID NO: 14), are incorporated in pCMV-T7-2 (SIBIA Inc.) using the overlapping cDNA clones cmR2, cmR3 and hcR7PCRl. A full-length hmGluR7b expression construct, designated pCMV-T7-hmGluR7b, is prepared by three- way-ligation of the Pstl/Bsal fragment of hcR7PCRl, the Bsal/Eagl fragment of cmR2 and the Pstl/Notl of pCMV-T7-2. Plasmid pCMV-T7-hmGluR7b contains the complete coding region of hmGluR7b and 191 nt of 3' untranslated sequences. To construct a full-length hmGluR7a expression construct, designated pCMV-T7-hmGluR7a, a 370 bp Hindπi/EagI fragment of cmR2 is exchanged with the corresponding fragment of cmR3. The Bsal/Eagl fragment of the resulting clone is used for a three-way-ligation as describe above. Plasmid pBK-CMV -hmGluRό is generated analogously using conventional techniques (Sambrook et al. supra). 4.2 Transfection of mammalian cells Mammalian cells (e.g. CHO-Kl, GH3; American Tissue Type Culture Collection) are adapted to grow in glutamate free medium (Dulbecco's modified Eagle's medium lacking L-glutamate and containing a reduced concentration of 2 mM L-glutamine, supplemented with 0.046 mg/ml proline and 10% dialyzed fetal bovine serum, Gibco-BRL). HmGluR expression plasmids are transiently transfected into the cells by calcium-phophate precipitation (Ausubel, F. M., et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, USA). Cell lines stably expressing hmGluRs are generated by lipofectin-mediated transfection (Gibco-BRL) of CHO-Kl cells with hmGluR expression plasmids and pSV2-Neo (Southern and Berg, 1982), a plasmid vector encoding the G-418 resistence gene. Cells are grown for 48 hours prior to the addition of 1 mg/ml G-418 sulfate (Geneticin, Gibco). Medium is replaced every two to three days. Cells surviving the G-418 selection are isolated and grown in the selection medium. 32 G-418 resistant clonal cell lines are analyzed six to eight weeks after the initial transfection for hmGluR protein expression by immunoreactivity with the anti-hmGluR7 antibody (immunodetection, cf. 4.3, infra) and functional responses following agonist addition via cAMP radioimmunoassay (cf. 5J, infra). Likewise, the hmGluR expression constructs pBK-CMV-hmGluR4, pCMV-T7-hmGluR4, pCMV-T7-hmGluR7b and pCMV-T7-hmGluR7a are transiently and stably expressed in mammalian cells (CVl, CHO, HEK293, COS) according to standard procedures (Ausubel, F. M., et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, USA). The transfected cells are analyzed for hmGluR expression by various assays: [ 3 H]-glutamate binding studies, immunocytochemistry using hmGluR subtype specific antibodies, and assays detecting a change in the intracellular concentration of cAMP ([cAMP]). 4.3 Immunodetection of hmGluR protein expression with subtype-specific hmGluR antibodies HmGluR protein expression is analyzed by immunocytochemistry with subtype-specific hmGluR antibodies (see Example 7). 1 to 3 days after transfection cells are washed twice with phosphate buffered saline (PBS), fixed with PBS/4% paraformaldehyde for 10 min and washed with PBS. Cells are permeabilized with PBS/0.4 % Triton X-100, followed by washing with PBS/10 mM glycine, and PBS. Cells are blocked with PBSTB (lx PBS/0J% Triton X- 100/1 % BSA) for 1 h and subsequently incubated with immunopurified hmGluR anϋ serum (0.5 - 2.0 μg/ml in PBSTB) for 1 h. After three washes with PBS, cells are incubated for 1 h with alkaline peroxidase conjugated goat anti-rabbit IgG (1:200 in PBSTB; Jackson Immuno Research). Cells are washed three times with PBS and immunoreactivity is detected with 0.4 mg/ml naphtolphosphate (Biorad)/l mg/ml Fast Red (Biorad)/10 mM Levamisole (Sigma)/100 mM Tris/HCl pH 8.8/100 mM NaCl 50 mM MgCl2- The staining reaction is stopped after 15 min by subsequent washing with PBS. 2 to 4 cell lines, each homogenously expressing hmGluR4, hmGluRό or hmGluR7, are identified by immunostaining. Example 5: Use of stable cell lines expressing hmGluRs for the screening of modulators of receptor activity Stable cell lines expressing hmGluR4, hmGluRό and hmGluR7 are used to screen for agonists, antagonists and allosteric modulators. Such compounds are identified by binding studies employing [ 3 H]glutamate and/or measurement of changes in intracellular second messenger levels ([cAMP], [Ca 2+ ]). 5.1 cAMP radioimmunoassay Ligand binding and agonist-induced depression of forskolin stimulated cAMP accumulation (changes in the intracellular cAMP concentration) are analyzed by cAMP radioimmunoassay (Amersham). Cells are seeded in 12-well plates at a density of 0.5-2.0 x 10-* cells per well and grown for 2 to 4 days until a confluent layer of cells is obtained. Cells are washed twice with PBS and incubated for 20 min in PBS containing 1 mM 3-isobutyl-l-methylxanthine (IBMX). Cells are incubated with fresh PBS containing 10 μM forskolin, 1 mM IBMX and a known hmGluR agonist for 20 min. The agonistic effect is stopped and cAMP produced by the cells is released by adding 1 ml of ethanol- water-HCl mix (100 ml of ethanol, 50 ml of water, 1 ml of 1 M HCl) after having aspirated the drug containing medium. cAMP levels are determined by a cAMP radioimmunoassay involving [ 3 H] cAMP (Amersham). HmGluR subtypes 4, 6 and 7 are negatively coupled to adenylate cyclase when expressed in CHO cells. Agonist binding leads to an inhibition of forskolin induced cAMP accumulation. All subtypes are AP-4 sensitive, meaning that AP 4 has an agonistic effect in a concentration less than 1 mM. 5.2 Measurement of intracellular [Ca 2+ ] Cells transformed with one of the above expression plasmids are loaded with a calcium sensitive fluorescent dye such as fura-2 or fluro-3. To achieve this cells are plated in single wells, single wells containing a coverslip, or 96-well plates and grown for 1 to 5 days until a 50-100 % confluent layer of cells is obtained. Wells are washed three times with a balance salt solution (BBS) and incubated for lh in BBS followed by three additional washings with BBS. Then cells are incubated for 20 to 60 min in a solution containing 50 μg fura-2-AM (or fluro3-AM) (Molecular Probes, Inc.) 4.99 ml BBS, 75 μl DMSO and 6.25 μg Pluronic (Molecular Probes, Inc). The cells are washed 3 times with BBS containing 2 mg/ml bovine albumin followed by three washes in BBS. After allowing recovery of the cells for at least 10 min they are used for microfluorometric measurements of [Ca 2+ ]. Cells are transferred to an apparatus for fluometry such as an inverted microscope, a spectra fluometer of a fluorescence reader. Fluorescence of the calcium indicator (e.g. fura-2 or fluo-3) is induced by illumination with light of a wavelength covered by the excitation spectrum of the dye (fura-2: 340/380 nm, fluo-3 3 480 nm). An increase in intracellular free claciom ion concentration is monitored as an increase of fura-2 or fluo-3 fluorescence excited at 340 nm and 480 nm, respectively, or a decrease of fura-2 fluorescence excited at 380 nm. As a positive control L-glutamate is applied at a concentration corresponding to its EC 50 value onto the cells, thereby inducing a measurable increase in the intracellular calcium ion concentration. A test compound is said to be an agonist if it induces a Ca 2+ signal comparable to that induced by glutamate. A test compound is said to be an antagonist if the glutamate induced calcium signal is smaller in the presence of the test compound than in the absence of the test compound. Example 6: Chimeric hmGluR4, 6 and 7 receptors Intracellular domains of mGluRl, particularly the second intracellular loop (i2) and the C-terminal region, have been shown to be critical for binding of G-proteins, which activate the phospholipase C/Ca 2+ signaling pathway, without changing the pharmacological profile of the receptor (Pin et al., EMBO J. 13, 342-348, (1994)). Conventional PCR mutagenesis techniques are used to exchange intracellular domains of hmGluRs 4,6, and 7 with corresponding domains of hmGluR 1. Stable CHO cell lines are generated with hmGluR4/l, 6/1 and 7/1 chimeric expression constructs allowing to analyze the influence of modulators of receptor activity (hmGluRs 4,6,7) using Ca 2+ -dependent assays. In the following, we describe the generation of a chimeric hmGluR7/l receptor. Expression constructs with chimeric hmGluR4/l and hmGluR6/l are generated using analogous cloning and PCR techniques, (i) The expression construct pCMV-hmGluR7b is digested with Eagl, thereby releasing the complete cDNA insert. The cDNA is cloned into the Notl site of pBluescript-Not, a derivative of pBluescript II (Stratagene) where the polylinker sequences between the unique Kpnl and Notl sites are deleted. The resulting clone is designated as pBluescript-Not-hmGluR7. (ii) The transmembrane region of hmGluR 1 is cloned by PCR using primers derived from Masu et al., 1991, supra. The oligonucleotide with the sequence 5 -TATCTTGAGTGGAGTGACATAG-3' (corresponding to nt 1753 to 1774 of the Masu sequence) is used as sense primer. The antisense primer has the sequence 5'-ACTGCGGACGTTCCTCTCAGG-3' corresponding to nt 2524 to 2544 of the Masu sequence. The C-terminal end of splice variants la, lb and lc is cleaved by PCR using primers derived from Masu et al., 1991, Tanabe et al., 1992, supra, and Pin et al., 1992 (Proc. Natl. Acad. Sci, USA, 89, 10331-10335 (1992)), respectively. The oligonucleotide having the sequence 5'-AAACCTGAGAGGAACGTCCGCAG-3' (corresponding to nt 2521 to nt 2543 of the Masu sequence) is used as sense primer. The oligonucleotides having the sequences 5'-CTACAGGGTGGAAGAGCTTTGCTT-3' corresponding to nt 3577 to 3600 of the Masu sequence, 5'-TCAAAGCTGCGCATGTGCCGACGG-3' corresponding to nt 2698 to 2721 of the Tanabe sequence, and 5'-TCAATAGACAGTG _TTTGGCGGTC-3' corresponding to nt 2671 to 2694 of the Pin sequence are used as antisense primers for hmGluRla, lb and lc, respectively. The PCR fragment is cloned into pBluescript II and sequenced completely, (iii) A chimeric cDNA fragment wherein the i2-loop of hmGluR7a or hmGluR7b (nt 2035 to 2106 of SEQ IDs 11 and 13, respectively) is replaced with the corresponding sequences of hmGluRl is generated by PCR (as described in Pin et al, 1994, supra). The fragment ist digested with Smal and Bgiπ which cut at unique restriction sites flanking the i2-loop. The chimeric Smal/Bgffl fragment is exchanged for the Smal/Bglll fragments of pBluescript-Not-mGluR7. (iv) Additional replacement of the C-terminal domain of hmGluR7b or hmGluR7a with the corresponding sequences of the above mentioned hmGluRl splice variants is achieved by using the unique restriction sites Bglll and SacII flanking the C-terminal end of hmGluR7. (v) The resulting chimeric hmGluR7/hmGluRl cDNAs are sequenced and digested with Eagl, thereby releasing the complete cDNAs from pBluescript-Not. For stable expression in CHO cells, the chimeric cDNAs are cloned into the unique Notl site of the mammalian expression vector pCMV -T 7-2. Example 7: Generation and application of anti-hmGluR antibodies Peptides corresponding to the deduced C-terminal amino acid sequences of hmGluR4 and hmGluR7 are synthesized and coupled to ovalbumin or Tentagel. Polyclonal antisera are raised in rabbits. Human mGluR specific antibodies are purified from the antisera by immunoaffmity chromatography on peptide columns. The hmGluR specific antibodies are characterized by ELISA and immunoblotting with glutathione-S-transferase/hmGluR fusion proteins (produced in E. coli) or human brain extracts. Antibodies specific for hmGluR4 and hmGluR7, respectively, are used to detect hmGluR receptors in transfected cells and to analyze the cellular and subcellular expression pattern of the hmGluR receptor proteins in tissue sections of human brain material. Antibodies are raised against different hmGluR-specifϊc peptides consisting of 20 amino acids and fusion proteins expressed in E.coli. Peptides are synthesized by solid-phase synthesis, coupled to keyhole limpit hemocyanin (KLH) or ovalbumin with glutaraldehyde. PCR fragments containing the entire putative intracellular C-terminal fragment of hmGluRs are cloned as BamHI/EcoRI fragments into the E. coli expression plasmid pGEX-2T (Guan and Dixon, Analytical Biochemistry 192, 262-267 (1991)) generating glutathione-S-transferase(GST)/hmGluR fusion genes. E. coli DH5a cells (Gibco-BRL) carrying expression plasmids with GST/hmGluR fusion genes are grown overnight at 37°C in LB medium 100 mg/ml ampicillin. The cultures are diluted 1:30 in LB and grown for 2 h at 30°C. Expression of fusion proteins is induced by treatment with 0J mM isopropyl-b-D-thiogalactopyranoside for 3 h at 30°C. Cells are harvested by centrifugation at 5,000 x g. The fusion protein is isolated using glutathione affinity chromatography. Deposition Data The following plasmids were deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg lb, D-38124 Braunschweig on September 13, 1993: Plasmid cmRl; accession no. DSM 8549 Plasmid cmR2; accession no. DSM 8550 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: CIBA-GEIGY AG (B) STREET: Klybeckstr. 141 (C) CITY: Basel (E) COUNTRY: SCHWEIZ (F) POSTAL CODE (ZIP) : 4002 (G) TELEPHONE: +41 61 69 11 11 (H) TELEFAX: + 41 61 696 79 76 (I) TELEX: 962 991 (ii) TITLE OF INVENTION: human receptor proteins (iii) NUMBER OF SEQUENCES: 16 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2739 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA ( ix ) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..2739 (D) OTHER INFORMATION: /product= "hmGluR4" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATG CCT GGG AAG AGA GGC TTG GGC TGG TGG TGG GCC CGG CTG CCC CTT 4 Met Pro Gly Lys Arg Gly Leu Gly Trp Trp Trp Ala Arg Leu Pro Leu 1 5 10 15 TGC CTG CTC CTC AGC CTT TAC GGC CCC TGG ATG CCT TCC TCC CTG GGA 9 Cys Leu Leu Leu Ser Leu Tyr Gly Pro Trp Met Pro Ser Ser Leu Gly 20 25 30 AAG CCC AAA GGC CAC CCT CAC ATG AAT TCC ATC CGC ATA GAT GGG GAC 1 Lys Pro Lys Gly His Pro His Met Asn Ser lie Arg lie Asp Gly Asp 35 40 45 ATC ACA CTG GGA GGC CTG TTC CCG GTG CAT GGC CGG GGC TCA GAG GGC 1 lie Thr Leu Gly Gly Leu Phe Pro Val His Gly Arg Gly Ser Glu Gly 50 55 60 AAG CCC TGT GGA GAA CTT AAG AAG GAA AAG GGC ATC CAC CGG CTG GAG 2 Lys Pro Cys Gly Glu Leu Lys Lys Glu Lys Gly lie His Arg Leu Glu 65 70 75 80 GCC ATG CTG TTC GCC CTG GAT CGC ATC AAC AAC GAC CCG GAC CTG CTG 2 Ala Met Leu Phe Ala Leu Asp Arg lie Asn Asn Asp Pro Asp Leu Leu 85 90 95 CCT AAC ATC ACG CTG GGC GCC CGC ATT CTG GAC ACC TGC TCC AGG GAC 336 Pro Asn lie Thr Leu Gly Ala Arg lie Leu Asp Thr Cys Ser Arg Asp 100 105 110 ACC CAT GCC CTC GAG CAG TCG CTG ACC TTT GTG CAG GCG CTC ATC GAG 384 Thr His Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu lie Glu 115 120 125 AAG GAT GGC ACA GAG GTC CGC TGT GGC AGT GGC GGC CCA CCC ATC ATC 432 Lys Asp Gly Thr Glu Val Arg Cys Gly Ser Gly Gly Pro Pro lie lie 130 135 140 ACC AAG CCT GAA CGT GTG GTG GGT GTC ATC GGT GCT TCA GGG AGC TCG 480 Thr Lys Pro Glu Arg Val Val Gly Val lie Gly Ala Ser Gly Ser Ser 145 150 155 160 GTC TCC ATC ATG GTG GCC AAC ATC CTT CGC CTC TTC AAG ATA CCC CAG 528 Val Ser lie Met Val Ala Asn lie Leu Arg Leu Phe Lys lie Pro Gin 165 170 175 ATC AGC TAC GCC TCC ACA GCG CCA GAC CTG AGT GAC AAC AGC CGC TAC 576 lie Ser Tyr Ala Ser Thr Ala Pro Asp Leu Ser Asp Asn Ser Arg Tyr 180 185 190 GAC TTC TTC TCC CGC GTG GTG CCC TCG GAC ACG TAC CAG GCC CAG GCC 624 Asp Phe Phe Ser Arg Val Val Pro Ser Asp Thr Tyr Gin Ala Gin Ala 195 200 205 ATG GTG GAC ATC GTC CGT GCC CTC AAG TGG AAC TAT GTG TCC ACA GTG 672 Met Val Asp lie Val Arg Ala Leu Lys Trp Asn Tyr Val Ser Thr Val 210 215 220 GCC TCG GAG GGC AGC TAT GGT GAG AGC GGT GTG GAG GCC TTC ATC CAG 720 Ala Ser Glu Gly Ser Tyr Gly Glu Ser Gly Val Glu Ala Phe He Gin 225 230 235 240 AAG TCC CGT GAG GAC GGG GGC GTG TGC ATC GCC CAG TCG GTG AAG ATA 768 Lys Ser Arg Glu Asp Gly Gly Val Cys He Ala Gin Ser Val Lys He 245 250 255 CCA CGG GAG CCC AAG GCA GGC GAG TTC GAC AAG ATC ATC CGC CGC CTC 816 Pro Arg Glu Pro Lys Ala Gly Glu Phe Asp Lys He He Arg Arg Leu 260 265 270 CTG GAG ACT TCG AAC GCC AGG GCA GTC ATC ATC TTT GCC AAC GAG GAT 864 Leu Glu Thr Ser Asn Ala Arg Ala Val He He Phe Ala Asn Glu Asp 275 280 285 GAC ATC AGG CGT GTG CTG GAG GCA GCA CGA AGG GCC AAC CAG ACA GGC 912 Asp He Arg Arg Val Leu Glu Ala Ala Arg Arg Ala Asn Gin Thr Gly 290 295 300 CAT TTC TTC TGG ATG GGC TCT GAC AGC TGG GGC TCC AAG ATT GCA CCT 960 His Phe Phe Trp Met Gly Ser Asp Ser Trp Gly Ser Lys He Ala Pro 305 310 315 320 GTG CTG CAC CTG GAG GAG GTG GCT GAG GGT GCT GTC ACG ATC CTC CCC 1008 Val Leu His Leu Glu Glu Val Ala Glu Gly Ala Val Thr He Leu Pro 325 330 335 AAG AGG ATG TCC GTA CGA GGC TTC GAC CGC TAC TTC TCC AGC CGC ACG 1056 Lys Arg Met Ser Val Arg Gly Phe Asp Arg Tyr Phe Ser Ser Arg Thr 340 345 350 CTG GAC AAC AAC CGG CGC AAC ATC TGG TTT GCC GAG TTC TGG GAG GAC 1104 Leu Asp Asn Asn Arg Arg Asn He Trp Phe Ala Glu Phe Trp Glu Asp 355 360 365 AAC TTC CAC TGC AAG CTG AGC CGC CAC GCC CTC AAG AAG GGC AGC CAC 1152 Asn Phe His Cys Lys Leu Ser Arg His Ala Leu Lys Lys Gly Ser His 370 375 380 GTC AAG AAG TGC ACC AAC CGT GAG CGA ATT GGG CAG GAT TCA GCT TAT 1200 Val Lys Lys Cys Thr Asn Arg Glu Arg He Gly Gin Asp Ser Ala Tyr 385 390 395 400 GAG CAG GAG GGG AAG GTG CAG TTT GTG ATC GAT- GCC GTG TAC GCC ATG 1248 Glu Gin Glu Gly Lys Val Gin Phe Val He Asp Ala Val Tyr Ala Met 405 410 415 GGC CAC GCG CTG CAC GCC ATG CAC CGT GAC CTG TGT CCC GGC CGC GTG 1296 Gly His Ala Leu His Ala Met His Arg Asp Leu Cys Pro Gly Arg Val 420 425 430 GGj CTC TGC CCG CGC ATG GAC CCT GTA GAT GGC ACC CAG CTG CTT AAG 1344 Gly Leu Cys Pro Arg Met Asp Pro Val Asp Gly Thr Gin Leu Leu Lys 435 440 445 TAC ATC CGA AAC GTC AAC TTC TCA GGC ATC GCA GGG AAC CCT GTG ACC 1392 Tyr He Arg Asn Val Asn Phe Ser Gly He Ala Gly Asn Pro Val Thr 450 455 460 TTC AAT GAG AAT GGA GAT GCG CCT GGG CGC TAT GAC ATC TAC CAA TAC 1440 Phe Asn Glu Asn Gly Asp Ala Pro Gly Arg Tyr Asp He Tyr Gin Tyr 465 470 475 480 CAG CTG CGC AAC GAT TCT GCC GAG TAC AAG GTC ATT GGC TCC TGG ACT 1488 Gin Leu Arg Asn Asp Ser Ala Glu Tyr Lys Val He Gly Ser Trp Thr 485 490 495 GAC CAC CTG CAC CTT AGA ATA GAG CGG ATG CAC TGG CCG GGG AGC GGG 1536 Asp His Leu His Leu Arg He Glu Arg Met His Trp Pro Gly Ser Gly 500 505 510 CAG CAG CTG CCC CGC TCC ATC TGC AGC CTG CCC TGC CAA CCG GGT GAG 1584 Gin Gin Leu Pro Arg Ser He Cys Ser Leu Pro Cys Gin Pro Gly Glu 515 520 525 CGG AAG AAG ACA GTG AAG GGC ATG CCT TGC TGC TGG CAC TGC GAG CCT 1632 Arg Lys Lys Thr Val Lys Gly Met Pro Cys Cys Trp His Cys Glu Pro 530 535 540 TGC ACA GGG TAC CAG TAC CAG GTG GAC CGC TAC ACC TGT AAG ACG TGT 168 Cys Thr Gly Tyr Gin Tyr Gin Val Asp Arg Tyr Thr Cys Lys Thr Cys 545 550 555 560 CCC TAT GAC ATG CGG CCC ACA GAG AAC CGC ACG GGC TGC CGG CCC ATC 172 Pro Tyr Asp Met Arg Pro Thr Glu Asn Arg Thr Gly Cys Arg Pro He 565 570 575 CCC ATC ATC AAG CTT GAG TGG GGC TCG CCC TGG GCC GTG CTG CCC CTC 177 Pro He He Lys Leu Glu Trp Gly Ser Pro Trp Ala Val Leu Pro Leu 580 585 590 TTC CTG GCC GTG GTG GGC ATC GCT GCC ACG TTG TTC GTG GTG ATC ACC 182 Phe Leu Ala Val Val Gly He Ala Ala Thr Leu Phe Val Val He Thr 595 600 605 TTT GTG CGC TAC AAC GAC ACG CCC ATC GTC AAG GCC TCG GGC CGT GAA 187 Phe Val Arg Tyr Asn Asp Thr Pro He Val Lys Ala Ser Gly Arg Glu 610 615 620 CTG AGC TAC GTG CTG CTG GCA GGC ATC TTC CTG TGC TAT GCC ACC ACC 192 Leu Ser Tyr Val Leu Leu Ala Gly He Phe Leu Cys Tyr Ala Thr Thr 625 630 635 640 TTC CTC ATG ATC GCT GAG CCC GAC CTT GGC ACC TGC TCG CTG CGC CGA 196 Phe Leu Met He Ala Glu Pro Asp Leu Gly Thr Cys Ser Leu Arg Arg 645 650 655 ATC TTC CTG GGA CTA GGG ATG AGC ATC AGC TAT GCA GCC CTG CTC ACC 201 He Phe Leu Gly Leu Gly Met Ser He Ser Tyr Ala Ala Leu Leu Thr 660 665 670 AAG ACC AAC CGC ATC TAC CGC ATC TTC GAG CAG GGC AAG CGC TCG GTC 2064 Lys Thr Asn Arg He Tyr Arg He Phe Glu Gin Gly Lys Arg Ser Val 675 680 685 AGT GCC CCA CGC TTC ATC AGC CCC GCC TCA CAG CTG GCC ATC ACC TTC 2112 Ser Ala Pro Arg Phe He Ser Pro Ala Ser Gin Leu Ala He Thr Phe 690 695 700 AGC CTC ATC TCG CTG CAG CTG CTG GGC ATC TGT GTG TGG TTT GTG GTG 2160 Ser Leu He Ser Leu Gin Leu Leu Gly He Cys Val Trp Phe Val Val 705 710 715 720 GAC CCC TCC CAC TCG GTG GTG GAC TTC CAG GAC CAG CGG ACA CTC GAC 2208 Asp Pro Ser His Ser Val Val Asp Phe Gin Asp Gin Arg Thr Leu Asp 725 730 735 CCC CGC TTC GCC AGG GGT GTG CTC AAG TGT GAC ATC TCG GAC CTG TCG 2256 Pro Arg Phe Ala Arg Gly Val Leu Lys Cys Asp He Ser Asp Leu Ser 740 745 750 CTC ATC TGC CTG CTG GGC TAC AGC ATG CTG CTC ATG GTC ACG TGC ACC 2304 Leu He Cys Leu Leu Gly Tyr Ser Met Leu Leu Met Val Thr Cys Thr 755 760 765 GTG TAT GCC ATC AAG ACA CGC GGC GTG CCC GAG ACC TTC AAT GAG GCC 2352 Val Tyr Ala He Lys Thr Arg Gly Val Pro Glu Thr Phe Asn Glu Ala 770 775 780 AAG CCC ATT GGC TTC ACC ATG TAC ACC ACT TGC ATC GTC TGG CTG GCC 2400 Lys Pro He Gly Phe Thr Met Tyr Thr Thr Cys He Val Trp Leu Ala 785 790 795 800 TTC ATC CCC ATC TTC TTT GGC ACC TCG CAG TCG GCC GAC AAG CTG TAC 2448 Phe He Pro He Phe Phe Gly Thr Ser Gin Ser Ala Asp Lys Leu Tyr 805 810 815 ATC CAG ACG ACG ACG CTG ACG GTC TCG GTG AGT CTG AGC GCC TCG GTG 2496 He Gin Thr Thr Thr Leu Thr Val Ser Val Ser Leu Ser Ala Ser Val 820 825 830 TCC CTG GGA ATG CTC TAC ATG CCC AAA GTC TAC ATC ATC CTC TTC CAC 2544 Ser Leu Gly Met Leu Tyr Met Pro Lys Val Tyr He He Leu Phe His 835 840 845 CCG GAG CAG AAC GTG CCC AAG CGC AAG CGC AGC CTC AAA GCC GTC GTT 2592 Pro Glu Gin Asn Val Pro Lys Arg Lys Arg Ser Leu Lys Ala Val Val 850 855 860 ACG GCG GCC ACC ATG TCC AAC AAG TTC ACG CAG AAG GGC AAC TTC CGG 2640 Thr Ala Ala Thr Met Ser Asn Lys Phe Thr Gin Lys Gly Asn Phe Arg 865 870 875 880 CCC AAC GGA GAG GCC AAG TCT GAG CTC TGC GAG AAC CTT GAG GCC CCA 2688 Pro Asn Gly Glu Ala Lys Ser Glu Leu Cys Glu Asn Leu Glu Ala Pro 885 890 895 GCG CTG GCC ACC AAA CAG ACT TAC GTC ACT TAC ACC AAC CAT GCA ATC 2736 Ala Leu Ala Thr Lys Gin Thr Tyr Val Thr Tyr Thr Asn His Ala He 900 905 910 TA 2739 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 912 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Pro Gly Lys Arg Gly Leu Gly Trp Trp Trp Ala Arg Leu Pro Leu 1 5 10 15 Cys Leu Leu Leu Ser Leu Tyr Gly Pro Trp Met Pro Ser Ser Leu Gly 20 25 30 Lys Pro Lys Gly His Pro His Met Asn Ser He Arg He Asp Gly Asp 35 40 45 He Thr Leu Gly Gly Leu Phe Pro Val His Gly Arg Gly Ser Glu Gly 50 55 60 Lys Pro Cys Gly Glu Leu Lys Lys Glu Lys Gly He His Arg Leu Glu 65 70 75 80 Ala Met Leu Phe Ala Leu Asp Arg He Asn Asn Asp Pro Asp Leu Leu 85 90 95 Pro Asn He Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 Thr His Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu He Glu 115 120 125 Lys Asp Gly Thr Glu Val Arg Cys Gly Ser Gly Gly Pro Pro He He 130 135 140 Thr Lys Pro Glu Arg Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Lys He Pro Gin 165 170 175 He Ser Tyr Ala Ser Thr Ala Pro Asp Leu Ser Asp Asn Ser Arg Tyr 180 185 190 Asp Phe Phe Ser Arg Val Val Pro Ser Asp Thr Tyr Gin Ala Gin Ala 195 200 205 Met Val Asp He Val Arg Ala Leu Lys Trp Asn Tyr Val Ser Thr Val 210 215 220 Ala Ser Glu Gly Ser Tyr Gly Glu Ser Gly Val Glu Ala Phe He Gin 225 230 235 240 Lys Ser Arg Glu Asp Gly Gly Val Cys He Ala Gin Ser Val Lys He 245 250 255 Pro Arg Glu Pro Lys Ala Gly Glu Phe Asp Lys He He Arg Arg Leu 260 265 270 Leu Glu Thr Ser Asn Ala Arg Ala Val He He Phe Ala Asn Glu Asp 275 280 285 Asp He Arg Arg Val Leu Glu Ala Ala Arg Arg Ala Asn Gin Thr Gly 290 295 300 His Phe Phe Trp Met Gly Ser Asp Ser Trp Gly Ser Lys He Ala Pro 305 310 315 320 Val Leu His Leu Glu Glu Val Ala Glu Gly Ala Val Thr He Leu Pro 325 330 335 Lys Arg Met Ser Val Arg Gly Phe Asp Arg Tyr Phe Ser Ser Arg Thr 340 345 350 Leu Asp Asn Asn Arg Arg Asn He Trp Phe Ala Glu Phe Trp Glu Asp 355 360 365 Asn Phe His Cys Lys Leu Ser Arg His Ala Leu Lys Lys Gly Ser His 370 375 380 Val Lys Lys Cys Thr Asn Arg Glu Arg He Gly Gin Asp Ser Ala Tyr 385 390 395 400 Glu Gin Glu Gly Lys Val Gin Phe Val He Asp Ala Val Tyr Ala Met 405 410 415 Gly His Ala Leu His Ala Met His Arg Asp Leu Cys Pro Gly Arg Val 420 425 430 Gly Leu Cys Pro Arg Met Asp Pro Val Asp Gly Thr Gin Leu Leu Lys 435 440 445 Tyr He Arg Asn Val Asn Phe Ser Gly He Ala Gly Asn Pro Val Thr 450 455 460 Phe Asn Glu Asn Gly Asp Ala Pro Gly Arg Tyr Asp He Tyr Gin Tyr 465 470 475 480 Gin Leu Arg Asn Asp Ser Ala Glu Tyr Lys Val He Gly Ser Trp Thr 485 490 495 Asp His Leu His Leu Arg He Glu Arg Met His Trp Pro Gly Ser Gly 500 505 510 Gin Gin Leu Pro Arg Ser He Cys Ser Leu Pro Cys Gin Pro Gly Glu 515 520 525 Arg Lys Lys Thr Val Lys Gly Met Pro Cys Cys Trp His Cys Glu Pro 530 535 540 Cys Thr Gly Tyr Gin Tyr Gin Val Asp Arg Tyr Thr Cys Lys Thr Cys 545 550 555 560 Pro Tyr Asp Met Arg Pro Thr Glu Asn Arg Thr Gly Cys Arg Pro He 565 570 575 Pro He He Lys Leu Glu Trp Gly Ser Pro Trp Ala Val Leu Pro Leu 580 585 590 Phe Leu Ala Val Val Gly He Ala Ala Thr Leu Phe Val Val He Thr 595 600 605 Phe Val Arg Tyr Asn Asp Thr Pro He Val Lys Ala Ser Gly Arg Glu 610 615 620 Leu Ser Tyr Val Leu Leu Ala Gly He Phe Leu Cys Tyr Ala Thr Thr 625 630 635 640 Phe Leu Met He Ala Glu Pro Asp Leu Gly Thr Cys Ser Leu Arg Arg 645 650 655 He Phe Leu Gly Leu Gly Met Ser He Ser Tyr Ala Ala Leu Leu Thr 660 665 670 Lys Thr Asn Arg He Tyr Arg He Phe Glu Gin Gly Lys Arg Ser Val 675 680 685 Ser Ala Pro Arg Phe He Ser Pro Ala Ser Gin Leu Ala He Thr Phe 690 695 700 Ser Leu He Ser Leu Gin Leu Leu Gly He Cys Val Trp Phe Val Val 705 710 715 720 Asp Pro Ser His Ser Val Val Asp Phe Gin Asp Gin Arg Thr Leu Asp 725 730 735 Pro Arg Phe Ala Arg Gly Val Leu Lys Cys Asp He Ser Asp Leu Ser 740 745 750 Leu He Cys Leu Leu Gly Tyr Ser Met Leu Leu Met Val Thr Cys Thr 755 760 765 Val Tyr Ala He Lys Thr Arg Gly Val Pro Glu Thr Phe Asn Glu Ala 770 775 780 Lys Pro He Gly Phe Thr Met Tyr Thr Thr Cys He Val Trp Leu Ala 785 790 795 800 Phe He Pro He Phe Phe Gly Thr Ser Gin Ser Ala Asp Lys Leu Tyr 805 810 815 He Gin Thr Thr Thr Leu Thr Val Ser Val Ser Leu Ser Ala Ser Val 820 825 830 Ser Leu Gly Met Leu Tyr Met Pro Lys Val Tyr He He Leu Phe His 835 840 845 Pro Glu Gin Asn Val Pro Lys Arg Lys Arg Ser Leu Lys Ala Val Val 850 855 860 Thr Ala Ala Thr Met Ser Asn Lys Phe Thr Gin Lys Gly Asn Phe Arg 865 870 875 880 Pro Asn Gly Glu Ala Lys Ser Glu Leu Cys Glu Asn Leu Glu Ala Pro 885 890 895 Ala Leu Ala Thr Lys Gin Thr Tyr Val Thr Tyr Thr Asn His Ala He 900 905 910 - 49 - (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3804 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2604 (D) OTHER INFORMATION: /product= "hmGluR7 encoding region of cmR2" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: CCC GTA CAC GCC AAG GGT CCC AGC GGA GTG CCC TGC GGC GAC ATC AAG 4 Pro Val His Ala Lys Gly Pro Ser Gly Val Pro Cys Gly Asp He Lys 1 5 10 15 AGG GAA AAC GGG ATC CAC AGG CTG GAA GCG ATG CTC TAC GCC CTG GAC 9 Arg Glu Asn Gly He His Arg Leu Glu Ala Met Leu Tyr Ala Leu Asp 20 25 30 CAG ATC AAC AGT GAT CCC AAC CTA CTG CCC AAC GTG ACG CTG GGC GCG 14 Gin He Asn Ser Asp Pro Asn Leu Leu Pro Asn Val Thr Leu Gly Ala 35 40 45 CGG ATC CTG GAC ACT TGT TCC AGG GAC ACT TAC GCG CTC GAA CAG TCG 192 Arg He Leu Asp Thr Cys Ser Arg Asp Thr Tyr Ala Leu Glu Gin Ser 50 55 60 CTT ACT TTC GTC CAG GCG CTC ATC CAG AAG GAC ACC TCC GAC GTG CGC 240 Leu Thr Phe Val Gin Ala Leu He Gin Lys Asp Thr Ser Asp Val Arg 65 70 75 80 TGC ACC AAC GGC GAA CCG CCG GTT TTC GTC AAG CCG GAG AAA GTA GTT 288 Cys Thr Asn Gly Glu Pro Pro Val phe Val Lys Pro Glu Lys Val Val 85 90 95 GGA GTG ATT GGG GCT TCG GGG AGT TCG GTC TCC ATC ATG GTA GCC AAC 336 Gly Val He Gly Ala Ser Gly Ser Ser Val Ser He Met Val Ala Asn 100 105 110 ATC CTG AGG CTC TTC CAG ATC CCC CAG ATT AGT TAT GCA TCA ACG GCA 384 He Leu Arg Leu Phe Gin He Pro Gin He Ser Tyr Ala Ser Thr Ala 115 120 125 CCC GAG CTA AGT GAT GAC CGG CGC TAT GAC TTC TTC TCT CGC GTG GTG 432 Pro Glu Leu Ser Asp Asp Arg Arg Tyr Asp Phe Phe Ser Arg Val Val 130 135 140 CCA CCC GAT TCC TTC CAA GCC CAG GCC ATG GTA GAC ATT GTA AAG GCC 480 Pro Pro Asp Ser Phe Gin Ala Gin Ala Met Val Asp He Val Lys Ala 145 150 155 160 CTA GGC TGG AAT TAT GTG TCT ACC CTC GCA TCG GAA GGA AGT TAT GGA 528 Leu Gly Trp Asn Tyr Val Ser Thr Leu Ala Ser Glu Gly Ser Tyr Gly 165 170 175 GAG AAA GGT GTG GAG TCC TTC ACG CAG ATT TCC AAA GAG GCA GGT GGA 576 Glu Lys Gly Val Glu Ser Phe Thr Gin He Ser Lys Glu Ala Gly Gly 180 185 190 CTC TGC ATT GCC CAG TCC GTG AGA ATC CCC CAG GAA CGC AAA GAC AGG 624 Leu Cys He Ala Gin Ser Val Arg He Pro Gin Glu Arg Lys Asp Arg 195 200 205 ACC ATT GAC TTT GAT AGA ATT ATC AAA CAG CTC CTG GAC ACC CCC AAC 672 Thr He Asp Phe Asp Arg He He Lys Gin Leu Leu Asp Thr Pro Asn 210 215 220 TCC AGG GCC GTC GTG ATT TTT GCC AAC GAT GAG GAT ATA AAG CAG ATC 720 Ser Arg Ala Val Val He Phe Ala Asn Asp Glu Asp He Lys Gin He 225 230 235 240 CTT GCA GCA GCC AAA AGA GCT GAC CAA GTT GGC CAT TTT CTT TGG GTG 768 Leu Ala Ala Ala Lys Arg Ala Asp Gin Val Gly His Phe Leu Trp Val 245 250 255 GGA TCA GAC AGC TGG GGA TCC AAA ATA AAC CCA CTG CAC CAG CAT GAA 816 Gly Ser Asp Ser Trp Gly Ser Lys He Asn Pro Leu His Gin His Glu 260 265 270 GAT ATC GCA GAA GGG GCC ATC ACC ATT CAG CCC AAG CGA GCC ACG GTG 864 Asp He Ala Glu Gly Ala He Thr He Gin Pro Lys Arg Ala Thr Val 275 280 285 GAA GGG TTT GAT GCC TAC TTT ACG TCC CGT ACA CTT GAA AAC AAC AGA 912 Glu Gly Phe Asp Ala Tyr Phe Thr Ser Arg Thr Leu Glu Asn Asn Arg 290 295 300 AGA AAT GTA TGG TTT GCC GAA TAC TGG GAG GAA AAC TTC AAC TGC AAG 96 Arg Asn Val Trp Phe Ala Glu Tyr Trp Glu Glu Asn Phe Asn Cys Lys 305 310 315 320 TTG ACG ATT AGT GGG TCA AAA AAA GAA GAC ACA GAT CGC AAA TGC ACA 100 Leu Thr He Ser Gly Ser Lys Lys Glu Asp Thr Asp Arg Lys Cys Thr 325 330 335 GGA CAG GAG AGA ATT GGA AAA GAT TCC AAC TAT GAG CAG GAG GGT AAA 1056 Gly Gin Glu Arg He Gly Lys Asp Ser Asn Tyr Glu Gin Glu Gly Lys 340 345 350 GTC CAG TTC GTG ATT GAC GCA GTC TAT GCT ATG GCT CAC GCC CTT CAC 1104 Val Gin Phe Val He Asp Ala Val Tyr Ala Met Ala His Ala Leu His 355 360 365 CAC ATG AAC AAG GAT CTC TGT GCT GAC TAC CGG GGT GTC TGC CCA GAG 1152 His Met Asn Lys Asp Leu Cys Ala Asp Tyr Arg Gly Val Cys Pro Glu 370 375 380 ATG GAG CAA GCT GGA GGC AAG AAG TTG CTG AAG TAT ATA CGC AAT GTT 1200 Met Glu Gin Ala Gly Gly Lys Lys Leu Leu Lys Tyr He Arg Asn Val 385 390 395 400 AAT TTC AAT GGT AGT GCT GGC ACT CCA GTG ATG TTT AAC AAG AAC GGG 1248 Asn Phe Asn Gly Ser Ala Gly Thr Pro Val Met Phe Asn Lys Asn Gly 405 410 415 GAT GCA CCT GGG CGT TAT GAC ATC TTT CAG TAC CAG ACC ACA AAC ACC 1296 Asp Ala Pro Gly Arg Tyr Asp He Phe Gin Tyr Gin Thr Thr Asn Thr 420 425 430 AGC AAC CCG GGT TAC CGT CTG ATC GGG CAG TGG ACA GAC GAA CTT CAG 1344 Ser Asn Pro Gly Tyr Arg Leu He Gly Gin Trp Thr Asp Glu Leu Gin 435 440 445 CTC AAT ATA GAA GAC ATG CAG TGG GGT AAA GGA GTC CGA GAG ATA CCC 1392 Leu Asn He Glu Asp Met Gin Trp Gly Lys Gly Val Arg Glu He Pro 450 455 460 GCC TCA GTG TGC ACA CTA CCA TGT AAG CCA GGA CAG AGA AAG AAG ACA 1440 Ala Ser Val Cys Thr Leu Pro Cys Lys Pro Gly Gin Arg Lys Lys Thr 465 470 475 480 CAG AAA GGA ACT CCT TGC TGT TGG ACC TGT GAG CCT TGC GAT GGT TAC 1488 Gin Lys Gly Thr Pro Cys Cys Trp Thr Cys Glu Pro Cys Asp Gly Tyr 485 490 495 CAG TAC CAG TTT GAT GAG ATG ACA TGC CAG CAT TGC CCC TAT GAC CAG 1536 Gin Tyr Gin Phe Asp Glu Met Thr Cys Gin His Cys Pro Tyr Asp Gin 500 505 510 AGG CCC AAT GAA AAT CGA ACC GGA TGC CAG GAT ATT CCC ATC ATC AAA 1584 Arg Pro Asn Glu Asn Arg Thr Gly Cys Gin Asp He Pro He He Lys 515 520 525 CTG GAG TGG CAC TCC CCC TGG GCT GTG ATT CCT GTC TTC CTG GCA ATG 1632 Leu Glu Trp His Ser Pro Trp Ala Val He Pro Val Phe Leu Ala Met 530 535 540 TTG GGG ATC ATT GCC ACC ATC TTT GTC ATG GCC ACT TTC ATC CGC TAC 1680 Leu Gly He He Ala Thr He Phe Val Met Ala Thr Phe He Arg Tyr 545 550 555 560 AAT GAC ACG CCC ATT GTC CGG GCA TCT GGG CGG GAA CTC AGC TAT GTT 1728 Asn Asp Thr Pro He Val Arg Ala Ser Gly Arg Glu Leu Ser Tyr Val 565 570 575 CTT TTG ACG GGC ATC TTT CTT TGC TAC ATC ATC ACT TTC CTG ATG ATT 1776 Leu Leu Thr Gly He Phe Leu Cys Tyr He He Thr Phe Leu Met He 580 585 590 GCC AAA CCA GAT GTG GCA GTG TGT TCT TTC CGG CGA GTT TTC TTG GGC 1824 Ala Lys Pro Asp Val Ala Val Cys Ser Phe Arg Arg Val Phe Leu Gly 595 600 605 TTG GGT ATG TGC ATC AGT TAT GCA GCC CTC TTG ACG AAA ACA AAT CGG 1872 Leu Gly Met Cys He Ser Tyr Ala Ala Leu Leu Thr Lys Thr Asn Arg 610 615 620 ATT TAT CGC ATA TTT GAG CAG GGC AAG AAA TCA GTA ACA GCT CCC AGA 1920 He Tyr Arg He Phe Glu Gin Gly Lys Lys Ser Val Thr Ala Pro Arg 625 630 635 640 CTC ATA AGC CCA ACA TCA CAA CTG GCA ATC ACT TCC AGT TTA ATA TCA 1968 Leu He Ser Pro Thr Ser Gin Leu Ala He Thr Ser Ser Leu He Ser 645 650 655 GTT CAG CTT CTA GGG GTG TTC ATT TGG TTT GGT GTT GAT CCA CCC AAC 2016 Val Gin Leu Leu Gly Val Phe He Trp Phe Gly Val Asp Pro Pro Asn 660 665 670 ATC ATC ATA GAC TAC GAT GAA CAC AAG ACA ATG AAC CCT GAG CAA GCC 206 He He He Asp Tyr Asp Glu His Lys Thr Met Asn Pro Glu Gin Ala 675 680 685 AGA GGG GTT CTC AAG TGT GAC ATT ACA GAT CTC CAA ATC ATT TGC TCC 211 Arg Gly Val Leu Lys Cys Asp He Thr Asp Leu Gin He He Cys Ser 690 695 700 TTG GGA TAT AGC ATT CTT CTC ATG GTC ACA TGT ACT GTG TAT GCC ATC 216 Leu Gly Tyr Ser He Leu Leu Met Val Thr Cys Thr Val Tyr Ala He 705 710 715 720 AAG ACT CGG GGT GTA CCC GAG AAT TTT AAC GAA GCC AAG CCC ATT GGA 220 Lys Thr Arg Gly Val Pro Glu Asn Phe Asn Glu Ala Lys Pro He Gly 725 730 735 TTC ACT ATG TAC ACG ACA TGT ATA GTA TGG CTT GCC TTC ATT CCA ATT 225 Phe Thr Met Tyr Thr Thr Cys He Val Trp Leu Ala Phe He Pro He 740 745 750 TTT TTT GGC ACC GCT CAA TCA GCG GAA AAG CTC TAC ATA CAA ACT ACC 230 Phe Phe Gly Thr Ala Gin Ser Ala Glu Lys Leu Tyr He Gin Thr Thr 755 760 765 ACG CTT ACA ATC TCC ATG AAC CTA AGT GCA TCA GTG GCG CTG GGG ATG 2352 Thr Leu Thr He Ser Met Asn Leu Ser Ala Ser Val Ala Leu Gly Met 770 775 780 CTA TAC ATG CCG AAA GTG TAC ATC ATC ATT TTC CAC CCT GAA CTC AAT 2400 Leu Tyr Met Pro Lys Val Tyr He He He Phe His Pro Glu Leu Asn 785 790 795 800 GTC CAG AAA CGG AAG CGA AGC TTC AAG GCG GTA GTC ACA GCA GCC ACC 2448 Val Gin Lys Arg Lys Arg Ser Phe Lys Ala Val Val Thr Ala Ala Thr 805 810 815 ATG TCA TCG AGG CTG TCA CAC AAA CCC AGT GAC AGA CCC AAC GGT GAG 2496 Met Ser Ser Arg Leu Ser His Lys Pro Ser Asp Arg Pro Asn Gly Glu 820 825 830 GCA AAG ACC GAG CTC TGT GAA AAC GTA GAC CCA AAC AAC TGT ATA CCA 2544 Ala Lys Thr Glu Leu Cys Glu Asn Val Asp Pro Asn Asn Cys He Pro 835 840 845 CCA GTA AGA AAG AGT GTA CAA AAG TCT GTT ACT TGG TAC ACT ATC CCA 2592 Pro Val Arg Lys Ser Val Gin Lys Ser Val Thr Trp Tyr Thr He Pro 850 855 860 CCA ACA GTA TAGCTTTTGA CTGCTTTCCC AAAGGCCCTG CTGCAAAAAA 2641 Pro Thr Val 865 GAAGTATGTC AGTTATAATA ACCTGGTTAT CTAACCTGTT CCATTCCATG GAACCATGGA 2701 GGAGGAAGAC CCTCAGTTAT TTTGTCACCC AACCTGGCAT AGGACTCTTT GGTCCTACCC 2761 GCTTCCCATC ACCGGAGGAG CTTCCCCGGC CGGGAGACCA GTGTTAGAGG ATCCAAGCGA 2821 CCTAAACAGC TGCTTTATGA AATATCCTTA CTTTATCTGG GCTTAATAAG TCACTGACAT 2881 CAGCACTGCC AACTTGGCTG CAATTGTGGA CCTTCCCTAC CAAAGGGAGT GTTGAAACTC 2941 AAGTCCCGCC CCGGCTCTTT AGAATGGACC ACTGAGAGCC ACAGGACCGT TTTGGGGCTG 3001 ACCTGTCTTA TTACGTATGT ACTTCTAGGT TGCAAGGTTT TGAAATTTTC TGTACAGTTT 3061 GTGAGGACCT TTGCACTTTG CCATCTGATG TCGTACCTCG GTTCACTGTT TGTTTTCGAA 3121 TGCCTTGTTT TCATAGAGCC CTATTCTCTC AGACGGTGGA ATATTTGGAA AAATTTTAAA 3181 ACAATTAAAA TTTTAAAGCA ATCTTGGCAG ACTAAAACAA GTACATCTGT ACATGACTGT 3241 ATAATTACGT TATAGTACCA CTGCACATCA TGTTTTTTTT TTTAAGACAA AAAAGATGTT 3301 TAAAGACCAA AAACTGTGCT GAGNAAGTAT GCCCCACCTA TCTTTNGNAT ATGATAGGTT 3361 ACATAAAAGG AAGGTATTGG CTGAACTGNA TAGAGGTCTT GATCTTTGGA ATGCATGCCA 3421 GTAATGTATT TACAGTACAT GTTTATTATG TTCAATATTT GTATTTGTGT TCTCTTTTGT 3481 TATTTTTAAT TAGNGTATAT GAATATTTTG CAATAATTTT AATAATTATT AAGCTGTTTG 3541 AAGGAAAGAA TATGGATTTT TCATGTCTTG AGGTTTTGTT CATGCCCCCT TTGACTGATC 3601 AGTGTGATAA GGACTTTAGG AAAAAAAGCA TGTATGTTTT TTACTGTTTG TAATAAGTAC 3661 TTTCGTTAAT CTTGCTGCTT ATGTGCCAAT TTAGTGGAAA AGAACAACCC TTGCTGAAAA 3721 ATTCCCTCTT TCCATTCTCT TTCAATTCTG TGATATTGTC CAAGAATGTA TCAATAAAAT 3781 ACTTTGGTTA ACTTTAAAAA AAA 3804 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 867 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Pro Val His Ala Lys Gly Pro Ser Gly Val Pro Cys Gly Asp He Lys 1 5 10 15 Arg Glu Asn Gly He His Arg Leu Glu Ala Met Leu Tyr Ala Leu Asp 20 25 30 Gin He Asn Ser Asp Pro Asn Leu Leu Pro Asn Val Thr Leu Gly Ala 35 40 45 Arg He Leu Asp Thr Cys Ser Arg Asp Thr Tyr Ala Leu Glu Gin Ser 50 55 60 Leu Thr Phe Val Gin Ala Leu He Gin Lys Asp Thr Ser Asp Val Arg 65 70 75 80 Cys Thr Asn Gly Glu Pro Pro Val Phe Val Lys Pro Glu Lys Val Val 85 90 95 Gly Val He Gly Ala Ser Gly Ser Ser Val Ser He Met Val Ala Asn 100 105 110 He Leu Arg Leu Phe Gin He Pro Gin He Ser Tyr Ala Ser Thr Ala 115 120 125 Pro Glu Leu Ser Asp Asp Arg Arg Tyr Asp Phe Phe Ser Arg Val Val 130 135 140 Pro Pro Asp Ser Phe Gin Ala Gin Ala Met Val Asp He Val Lys Ala 145 150 155 160 Leu Gly Trp Asn Tyr Val Ser Thr Leu Ala Ser Glu Gly Ser Tyr Gly 165 170 175 Glu Lys Gly Val Glu Ser Phe Thr Gin He Ser Lys Glu Ala Gly Gly 180 185 190 Leu Cys He Ala Gin Ser Val Arg He Pro Gin Glu Arg Lys Asp Arg 195 200 205 Thr He Asp Phe Asp Arg He He Lys Gin Leu Leu Asp Thr Pro Asn 210 215 220 Ser Arg Ala Val Val He Phe Ala Asn Asp Glu Asp He Lys Gin He 225 230 235 . 240 Leu Ala Ala Ala Lys Arg Ala Asp Gin Val Gly His Phe Leu Trp Val 245 250 255 Gly Ser Asp Ser Trp Gly Ser Lys He Asn Pro Leu His Gin His Glu 260 265 270 Asp He Ala Glu Gly Ala He Thr He Gin Pro Lys Arg Ala Thr Val 275 280 285 Glu Gly Phe Asp Ala Tyr Phe Thr Ser Arg Thr Leu Glu Asn Asn Arg 290 295 300 Arg Asn Val Trp Phe Ala Glu Tyr Trp Glu Glu Asn Phe Asn Cys Lys 305 310 315 320 Leu Thr He Ser Gly Ser Lys Lys Glu Asp Thr Asp Arg Lys Cys Thr 325 330 335 Gly Gin Glu Arg He Gly Lys Asp Ser Asn Tyr Glu Gin Glu Gly Lys 340 345 350 Val Gin Phe Val He Asp Ala Val Tyr Ala Met Ala His Ala Leu His 355 360 365 His Met Asn Lys Asp Leu Cys Ala Asp Tyr Arg Gly Val Cys Pro Glu 370 375 380 Met Glu Gin Ala Gly Gly Lys Lys Leu Leu Lys Tyr He Arg Asn Val 385 390 395 400 Asn Phe Asn Gly Ser Ala Gly Thr Pro Val Met Phe Asn Lys Asn Gly 405 410 415 Asp Ala Pro Gly Arg Tyr Asp He Phe Gin Tyr Gin Thr Thr Asn Thr 420 425 430 Ser Asn Pro Gly Tyr Arg Leu He Gly Gin Trp Thr Asp Glu Leu Gin 435 440 445 Leu Asn He Glu Asp Met Gin Trp Gly Lys Gly Val Arg Glu He Pro 450 455 460 Ala Ser Val Cys Thr Leu Pro Cys Lys Pro Gly Gin Arg Lys Lys Thr 465 470 475 480 Gin Lys Gly Thr Pro Cys Cys Trp Thr Cys Glu Pro Cys Asp Gly Tyr 485 490 495 Gin Tyr Gin Phe Asp Glu Met Thr Cys Gin His Cys Pro Tyr Asp Gin 500 505 510 Arg Pro Asn Glu Asn Arg Thr Gly Cys Gin Asp He Pro He He Lys 515 520 525 Leu Glu Trp His Ser Pro Trp Ala Val He Pro Val Phe Leu Ala Met 530 535 540 Leu Gly He He Ala Thr He Phe Val Met Ala Thr Phe He Arg Tyr 545 550 555 560 Asn Asp Thr Pro He Val Arg Ala Ser Gly Arg Glu Leu Ser Tyr Val 565 570 575 Leu Leu Thr Gly He Phe Leu Cys Tyr He He Thr Phe Leu Met He 580 585 590 Ala Lys Pro Asp Val Ala Val Cys Ser Phe Arg Arg Val Phe Leu Gly 595 600 605 Leu Gly Met Cys He Ser Tyr Ala Ala Leu Leu Thr Lys Thr Asn Arg 610 615 620 He Tyr Arg He Phe Glu Gin Gly Lys Lys Ser Val Thr Ala Pro Arg 625 630 635 640 Leu He Ser Pro Thr Ser Gin Leu Ala He Thr Ser Ser Leu He Ser 645 650 655 Val Gin Leu Leu Gly Val Phe He Trp Phe Gly Val Asp Pro Pro Asn 660 665 670 He He He Asp Tyr Asp Glu His Lys Thr Met Asn Pro Glu Gin Ala 675 680 685 Arg Gly Val Leu Lys Cys Asp He Thr Asp Leu Gin He He Cys Ser 690 695 700 Leu Gly Tyr Ser He Leu Leu Met Val Thr Cys Thr Val Tyr Ala He 705 710 715 720 Lys Thr Arg Gly Val Pro Glu Asn Phe Asn Glu Ala Lys Pro He Gly 725 730 735 Phe Thr Met Tyr Thr Thr Cys He Val Trp Leu Ala Phe He Pro He 740 745 750 Phe Phe Gly Thr Ala Gin Ser Ala Glu Lys Leu Tyr He Gin Thr Thr 755 760 765 Thr Leu Thr He Ser Met Asn Leu Ser Ala Ser Val Ala Leu Gly Met 770 775 780 Leu Tyr Met Pro Lys Val Tyr He He He Phe His Pro Glu Leu Asn 785 790 795 800 Val Gin Lys Arg Lys Arg Ser Phe Lys Ala Val Val Thr Ala Ala Thr 805 810 815 Met Ser Ser Arg Leu Ser His Lys Pro Ser Asp Arg Pro Asn Gly Glu 820 825 830 Ala Lys Thr Glu Leu Cys Glu Asn Val Asp Pro Asn Asn Cys He Pro 835 840 845 Pro Val Arg Lys Ser Val Gin Lys Ser Val Thr Trp Tyr Thr He Pro 850 855 860 Pro Thr Val 865 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1399 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..270 (D) OTHER INFORMATION: /produc = "hmGluR7 encoding region of cmR3" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ATC TCC ATG AAC CTA AGT GCA TCA GTG GCG CTG GGG ATG CTA TAC ATG 48 He Ser Met Asn Leu Ser Ala Ser Val Ala Leu Gly Met Leu Tyr Met 1 5 10 15 CCG AAA GTG TAC ATC ATC ATT TTC CAC CCT GAA CTC AAT GTC CAG AAA 96 Pro Lys Val Tyr He He He Phe His Pro Glu Leu Asn Val Gin Lys 20 25 30 CGG AAG CGA AGC TTC AAG GCG GTA GTC ACA GCA GCC ACC ATG TCA TCG 144 Arg Lys Arg Ser Phe Lys Ala Val Val Thr Ala Ala Thr Met Ser Ser 35 40 45 AGG CTG TCA CAC AAA CCC AGT GAC AGA CCC AAC GGT GAG GCA AAG ACC 192 Arg Leu Ser His Lys Pro Ser Asp Arg Pro Asn Gly Glu Ala Lys Thr 50 55 60 GAG CTC TGT GAA AAC GTA GAC CCA AAC AGC CCT GCT GCA AAA AAG AAG 240 Glu Leu Cys Glu Asn Val Asp Pro Asn Ser Pro Ala Ala Lys Lys Lys 65 70 75 80 TAT GTC AGT TAT AAT AAC CTG GTT ATC TAACCTGTTC CATTCCATGG 287 Tyr Val Ser Tyr Asn Asn Leu Val He 85 90 AACCATGGAG GAGGAAGACC CTCAGTTATT TTGTCACCCA ACCTGGCATA GGACTCTTTG 347 GTCCTACCCG CTTCCCATCA CCGGAGGAGC TTCCCCGGCC GGGAGACCAG TGTTAGAGGA 407 TCCAAGCGAC CTAAACAGCT GCTTTATGAA ATATCCTTAC TTTATCTGGG CTTAATAAGT 467 CACTGACATC AGCACTGCCA ACTTGGCTGC AATTGTGGAC CTTCCCTACC AAAGGGAGTG 527 TTGAAACTCA AGTCCCGCCC CGGCTCTTTA GAATGGACCA CTGAGAGCCA CAGGACCGTT 587 TTGGGGCTGA CCTGTCTTAT TACGTATGTA CTTCTAGGTT GCAAGGTTTT GAAATTTTCT 647 GTACAGTTTG TGAGGACCTT TGCACTTTGC CATCTGATGT CGTACCTCGG TTCACTGTTT 707 GTTTTCGAAT GCCTTGTTTT CATAGAGCCC TATTCTCTCA GACGGTGGAA TATTTGGAAA 767 AATTTTAAAA CAATTAAAAT TTTAAAGCAA TCTTGGCAGA CTAAAACAAG TACATCTGTA 827 CATGACTGTA TAATTACGTT ATAGTACCAC TGCACATCAT GTTTTTTTTT TTAAGACAAA 887 AAAGATGTTT AAAGACCAAA AACTGTGCTG AGNAAGTATG CCCCACCTAT CTTTNGNATA 947 TGATAGGTTA CATAAAAGGA AGGTATTGGC TGAACTGNAT AGAGGTCTTG ATCTTTGGAA 1007 TGCATGCCAG TAATGTATTT ACAGTACATG TTTATTATGT TCAATATTTG TATTTGTGTT 1067 CTCTTTTGTT ATTTTTAATT AGNGTATATG AATATTTTGC AATAATTTTA ATAATTATTA 1127 AGCTGTTTGA AGGAAAGAAT ATGGATTTTT CATGTCTTGA GGTTTTGTTC ATGCCCCCTT 1187 TGACTGATCA GTGTGATAAG GACTTTAGGA AAAAAAGCAT GTATGTTTTT TACTGTTTGT 1247 AATAAGTACT TTCGTTAATC TTGCTGCTTA TGTGCCAATT TAGTGGAAAA GAACAACCCT 1307 TGCTGAAAAA TTCCCTCTTT CCATTCTCTT TCAATTCTGT GATATTGTCC AAGAATGTAT 1367 CAATAAAATA CTTTGGTTAA CTTTAAAAAA AA 1399 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 89 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: He Ser Met Asn Leu Ser Ala Ser Val Ala Leu Gly Met Leu Tyr Met 1 5 10 15 Pro Lys Val Tyr He He He Phe His Pro Glu Leu Asn Val Gin Lys 20 25 30 Arg Lys Arg Ser Phe Lys Ala Val Val Thr Ala Ala Thr Met Ser Ser 35 40 45 Arg Leu Ser His Lys Pro Ser Asp Arg Pro Asn Gly Glu Ala Lys Thr 50 55 60 Glu Leu Cys Glu Asn Val Asp Pro Asn Ser Pro Ala Ala Lys Lys Lys 65 70 75 80 Tyr Val Ser Tyr Asn Asn Leu Val He 85 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1588 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..1447 (D) OTHER INFORMATION: /product= "hmGluR7 encodingportion of cmR5" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: G AAC AAG GAT CTC TGT GCT GAC TAC CGG GGT GTC TGC CCA GAG ATG Asn Lys Asp Leu Cys Ala Asp Tyr Arg Gly Val Cys Pro Glu Met 1 5 10 15 GAG CAA GCT GGA GGC AAG AAG TTG CTG AAG TAT ATA CGC AAT GTT AAT Glu Gin Ala Gly Gly Lys Lys Leu Leu Lys Tyr He Arg Asn Val Asn 20 25 30 TTC AAT GGT AGT GCT GGC ACT CCA GTG ATG TTT AAC AAG AAC GGG GAT 1 Phe Asn Gly Ser Ala Gly Thr Pro Val Met Phe Asn Lys Asn Gly Asp 35 40 45 GCA CCT GGG CGT TAT GAC ATC TTT CAG TAC CAG ACC ACA AAC ACC AGC 190 Ala Pro Gly Arg Tyr Asp He Phe Gin Tyr Gin Thr Thr Asn Thr Ser 50 55 60 AAC CCG GGT TAC CGT CTG ATC GGG CAG TGG ACA GAC GAA CTT CAG CTC 238 Asn Pro Gly Tyr Arg Leu He Gly Gin Trp Thr Asp Glu Leu Gin Leu 65 70 75 AAT ATA GAA GAC ATG CAG TGG GGT AAA GGA GTC CGA GAG ATA CCC GCC 286 Asn He Glu Asp Met Gin Trp Gly Lys Gly Val Arg Glu He Pro Ala 80 85 90 95 TCA GTG TGC ACA CTA CCA TGT AAG CCA GGA CAG AGA AAG AAG ACA CAG 334 Ser Val Cys Thr Leu Pro Cys Lys Pro Gly Gin Arg Lys Lys Thr Gin 100 105 110 AAA GGA ACT CCT TGC TGT TGG ACC TGT GAG CCT TGC GAT GGT TAC CAG 382 Lys Gly Thr Pro Cys Cys Trp Thr Cys Glu Pro Cys Asp Gly Tyr Gin 115 120 125 TAC CAG TTT GAT GAG ATG ACA TGC CAG CAT TGC CCC TAT GAC CAG AGG 430 Tyr Gin Phe Asp Glu Met Thr Cys Gin His Cys Pro Tyr Asp Gin Arg 130 135 140 CCC AAT GAA AAT CGA ACC GGA TGC CAG GAT ATT CCC ATC ATC AAA CTG 478 Pro Asn Glu Asn Arg Thr Gly Cys Gin Asp He Pro He He Lys Leu 145 150 155 GAG TGG CAC TCC CCC TGG GCT GTG ATT CCT GTC TTC CTG GCA ATG TTG 52 Glu Trp His Ser Pro Trp Ala Val He Pro Val Phe Leu Ala Met Leu 160 165 170 175 GGG ATC ATT GCC ACC ATC TTT GTC ATG GCC ACT TTC ATC CGC TAC AAT 574 Gly He He Ala Thr He Phe Val Met Ala Thr Phe He Arg Tyr Asn 180 185 190 GAC ACG CCC ATT GTC CGG GCA TCT GGG CGG GAA CTC AGC TAT GTT CTT 622 Asp Thr Pro He Val Arg Ala Ser Gly Arg Glu Leu Ser Tyr Val Leu 195 200 205 TTG ACG GGC ATC TTT CTT TGC TAC ATC ATC ACT TTC CTG ATG ATT GCC 670 Leu Thr Gly He Phe Leu Cys Tyr He He Thr Phe Leu Met He Ala 210 215 220 AAA CCA GAT GTG GCA GTG TGT TCT TTC CGG CGA GTT TTC TTG GGC TTG 718 Lys Pro Asp Val Ala Val Cys Ser Phe Arg Arg Val Phe Leu Gly Leu 225 230 235 GGT ATG TGC ATC AGT TAT GCA GCC CTC TTG ACG AAA ACA AAT CGG ATT 76 Gly Met Cys He Ser Tyr Ala Ala Leu Leu Thr Lys Thr Asn Arg He 240 245 250 255 TAT CGC ATA TTT GAG CAG GGC AAG AAA TCA GTA ACA GCT CCC AGA CTC 81 Tyr Arg He Phe Glu Gin Gly Lys Lys Ser Val Thr Ala Pro Arg Leu 260 265 270 ATA AGC CCA ACA TCA CAA CTG GCA ATC ACT TCC AGT TTA ATA TCA GTT 86 He Ser Pro Thr Ser Gin Leu Ala He Thr Ser Ser Leu He Ser Val 275 280 285 CAG CTT CTA GGG GTG TTC ATT TGG TTT GGT GTT GAT CCA CCC AAC ATC 91 Gin Leu Leu Gly Val Phe He Trp Phe Gly Val Asp Pro Pro Asn He 290 295 300 ATC ATA GAC TAC GAT GAA CAC AAG ACA ATG AAC CCT GAG CAA GCC AGA 95 He He Asp Tyr Asp Glu His Lys Thr Met Asn Pro Glu Gin Ala Arg 305 310 315 GGG GTT CTC AAG TGT GAC ATT ACA GAT CTC CAA ATC ATT TGC TCC TTG 100 Gly Val Leu Lys Cys Asp He Thr Asp Leu Gin He He Cys Ser Leu 320 325 330 335 GGA TAT AGC ATT CTT CTC ATG GTC ACA TGT ACT GTG TAT GCC ATC AAG 105 Gly Tyr Ser He Leu Leu Met Val Thr Cys Thr Val Tyr Ala He Lys 340 345 350 ACT CGG GGT GTA CCC GAG AAT TTT AAC GAA GCC AAG CCC ATT GGA TTC 110 Thr Arg Gly Val Pro Glu Asn Phe Asn Glu Ala Lys Pro He Gly Phe 355 360 365 ACT ATG TAC ACG ACA TGT ATA GTA TGG CTT GCC TTC ATT CCA ATT TTT 115 Thr Met Tyr Thr Thr Cys He Val Trp Leu Ala Phe He Pro He Phe 370 375 380 TTT GGC ACC GCT CAA TCA GCG GAA AAG CTC TAC ATA CAA ACT ACC ACG 119 Phe Gly Thr Ala Gin Ser Ala Glu Lys Leu Tyr He Gin Thr Thr Thr 385 390 395 CTT ACA ATC TCC ATG AAC CTA AGT GCA TCA GTG GCG CTG GGG ATG CTA 124 Leu Thr He Ser Met Asn Leu Ser Ala Ser Val Ala Leu Gly Met Leu 400 405 410 415 TAC ATG CCG AAA GTG TAC ATC ATC ATT TTC CAC CCT GAA CTC AAT GTC 129 Tyr Met Pro Lys Val Tyr He He He Phe His Pro Glu Leu Asn Val 420 425 430 CAG AAA CGG AAG CGA AGC TTC AAG GCG GTA GTC ACA GCA GCC ACC ATG 134 Gin Lys Arg Lys Arg Ser Phe Lys Ala Val Val Thr Ala Ala Thr Met 435 440 445 TCA TCG AGG CTG TCA CAC AAA CCC AGT GAC AGA CCC AAC GGT GAG GCA 139 Ser Ser Arg Leu Ser His Lys Pro Ser Asp Arg Pro Asn Gly Glu Ala 450 455 460 AAG ACC GAG CTC TGT GAA AAC GTA GAC CCA AAC AGT GAG AAG TGC AAC 143 Lys Thr Glu Leu Cys Glu Asn Val Asp Pro Asn Ser Glu Lys Cys Asn 465 470 475 TGC TAC TGACCATCTG CACTGGCATC TAGTCAAGCG ATTGTCTGAG GAAAGGATTT 1494 Cys Tyr 480 TGGAGATTCC CATCTGATAT TCTTCTATTT GGTCTCTTGT ACCCATTGTC ATCCTGTACC 1554 ACACATAATA AAGTTTAAGA ATGTCAAGCA AAAG 1588 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 481 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Asn Lys Asp Leu Cys Ala Asp Tyr Arg Gly Val Cys Pro Glu Met Glu 1 5 10 15 Gin Ala Gly Gly Lys Lys Leu Leu Lys Tyr He Arg Asn Val Asn Phe 20 25 30 Asn Gly Ser Ala Gly Thr Pro Val Met Phe Asn Lys Asn Gly Asp Ala 35 40 45 Pro Gly Arg Tyr Asp He Phe Gin Tyr Gin Thr Thr Asn Thr Ser Asn 50 55 60 Pro Gly Tyr Arg Leu He Gly Gin Trp Thr Asp Glu Leu Gin Leu Asn 65 70 75 80 He Glu Asp Met Gin Trp Gly Lys Gly Val Arg Glu He Pro Ala Ser 85 90 95 Val Cys Thr Leu Pro Cys Lys Pro Gly Gin Arg Lys Lys Thr Gin Lys 100 105 110 Gly Thr Pro Cys Cys Trp Thr Cys Glu Pro Cys Asp Gly Tyr Gin Tyr 115 120 125 Gin Phe Asp Glu Met Thr Cys Gin His Cys Pro Tyr Asp Gin Arg Pro 130 135 140 Asn Glu Asn Arg Thr Gly Cys Gin Asp He Pro He He Lys Leu Glu 145 150 155 160 Trp His Ser Pro Trp Ala Val He Pro Val Phe Leu Ala Met Leu Gly 165 170 175 He He Ala Thr He Phe Val Met Ala Thr Phe He Arg Tyr Asn Asp 180 185 190 Thr Pro He Val Arg Ala Ser Gly Arg Glu Leu Ser Tyr Val Leu Leu 195 200 205 Thr Gly He Phe Leu Cys Tyr He He Thr Phe Leu Met He Ala Lys 210 215 220 Pro Asp Val Ala Val Cys Ser Phe Arg Arg Val Phe Leu Gly Leu Gly 225 230 235 240 Met Cys He Ser Tyr Ala Ala Leu Leu Thr Lys Thr Asn Arg He Tyr 245 250 255 Arg He Phe Glu Gin Gly Lys Lys Ser Val Thr Ala Pro Arg Leu He 260 265 270 Ser Pro Thr Ser Gin Leu Ala He Thr Ser Ser Leu He Ser Val Gin 275 280 285 Leu Leu Gly Val Phe He Trp Phe Gly Val Asp Pro Pro Asn He He 290 295 300 He Asp Tyr Asp Glu His Lys Thr Met Asn Pro Glu Gin Ala Arg Gly 305 310 315 320 Val Leu Lys Cys Asp He Thr Asp Leu Gin He He Cys Ser Leu Gly 325 330 335 Tyr Ser He Leu Leu Met Val Thr Cys Thr Val Tyr Ala He Lys Thr 340 345 350 Arg Gly Val Pro Glu Asn Phe Asn Glu Ala Lys Pro He Gly Phe Thr 355 360 365 Met Tyr Thr Thr Cys He Val Trp Leu Ala Phe He Pro He Phe Phe 370 375 380 Gly Thr Ala Gin Ser Ala Glu Lys Leu Tyr He Gin Thr Thr Thr Leu 385 390 395 400 Thr He Ser Met Asn Leu Ser Ala Ser Val Ala Leu Gly Met Leu Tyr 405 410 415 Met Pro Lys Val Tyr He He He Phe His Pro Glu Leu Asn Val Gin 420 425 430 Lys Arg Lys Arg Ser Phe Lys Ala Val Val Thr Ala Ala Thr Met Ser 435 440 445 Ser Arg Leu Ser His Lys Pro Ser Asp Arg Pro Asn Gly Glu Ala Lys 450 455 460 Thr Glu Leu Cys Glu Asn Val Asp Pro Asn Ser Glu Lys Cys Asn Cys 465 470 475 480 Tyr (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 558 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..558 (D) OTHER INFORMATION: /product= "hmGluR7 encodingportion of CR7PCR1" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: ATG GTC CAG CTG AGG AAG CTG CTC CGC GTC CTG ACT TTG ATG AAG TTC 4 Met Val Gin Leu Arg Lys Leu Leu Arg Val Leu Thr Leu Met Lys Phe 1 5 10 15 CCC TGC TGC GTG CTG GAG GTG CTC CTG TGC GCG CTG GCG GCG GCG GCG 9 Pro Cys Cys Val Leu Glu Val Leu Leu Cys Ala Leu Ala Ala Ala Ala 20 25 30 CGC GGC CAG GAG ATG TAC GCC CCG CAC TCA ATC CGG ATC GAG GGG GAC 14 Arg Gly Gin Glu Met Tyr Ala Pro His Ser He Arg He Glu Gly Asp 35 40 45 GTC ACC CTC GGG GGG CTG TTC CCC GTA CAC GCC AAG GGT CCC AGC GGA 19 Val Thr Leu Gly Gly Leu Phe Pro Val His Ala Lys Gly Pro Ser Gly 50 55 60 GTG CCC TGC GGC GAC ATC AAG AGG GAA AAC GGG ATC CAC AGG CTG GAA 24 Val Pro Cys Gly Asp He Lys Arg Glu Asn Gly He His Arg Leu Glu 65 70 75 80 GCG ATG CTC TAC GCC CTG GAC CAG ATC AAC AGT GAT CCC AAC CTA CTG 28 Ala Met Leu Tyr Ala Leu Asp Gin He Asn Ser Asp Pro Asn Leu Leu 85 90 95 CCC AAC GTG ACG CTG GGC GCG CGG ATC CTG GAC ACT TGT TCC AGG GAC 33 Pro Asn Val Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 ACT TAC GCG CTC GAA CAG TCG CTT ACT TTC GTC CAG GCG CTC ATC CAG 38 Thr Tyr Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu He Gin 115 120 125 AAG GAC ACC TCC GAC GTG CGC TGC ACC AAC GGC GAA CCG CCG GTT TTC 43 Lys Asp Thr Ser Asp Val Arg Cys Thr Asn Gly Glu Pro Pro Val Phe 130 135 140 GTC AAG CCG GAG AAA GTA GTT GGA GTG ATT GGG GCT TCG GGG AGT TCG 48 Val Lys Pro Glu Lys Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 GTC TCC ATC ATG GTA GCC AAC ATC CTG AGG CTC TTC CAG ATC CCC CAG 52 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Gin He Pro Gin 165 170 175 ATT AGT TAT GCA TCA ACG GCA CCC GAG CTA 55 He Ser Tyr Ala Ser Thr Ala Pro Glu Leu 180 185 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 186 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Met Val Gin Leu Arg Lys Leu Leu Arg Val Leu Thr Leu Met Lys Phe 1 5 10 15 Pro Cys Cys Val Leu Glu Val Leu Leu Cys Ala Leu Ala Ala Ala Ala 20 25 30 Arg Gly Gin Glu Met Tyr Ala Pro His Ser He Arg He Glu Gly Asp 35 40 45 Val Thr Leu Gly Gly Leu Phe Pro Val His Ala Lys Gly Pro Ser Gly 50 55 60 Val Pro Cys Gly Asp He Lys Arg Glu Asn Gly He His Arg Leu Glu 65 70 75 80 Ala Met Leu Tyr Ala Leu Asp Gin He Asn Ser Asp Pro Asn Leu Leu 85 90 95 Pro Asn Val Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 Thr Tyr Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu He Gin 115 120 125 Lys Asp Thr Ser Asp Val Arg Cys Thr Asn Gly Glu Pro Pro Val Phe 130 135 140 Val Lys Pro Glu Lys Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Gin He Pro Gin 165 170 175 He Ser Tyr Ala Ser Thr Ala Pro Glu Leu 180 185 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2748 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2748 (D) OTHER INFORMATION: /product= "h__GluR7a" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATG GTC CAG CTG AGG AAG CTG CTC CGC GTC CTG ACT TTG ATG AAG TTC Met Val Gin Leu Arg Lys Leu Leu Arg Val Leu Thr Leu Met Lys Phe 1 5 10 15 CCC TGC TGC GTG CTG GAG GTG CTC CTG TGC GCG CTG GCG GCG GCG GCG 96 Pro Cys Cys Val Leu Glu Val Leu Leu Cys Ala Leu Ala Ala Ala Ala 20 25 30 CGC GGC CAG GAG ATG TAC GCC CCG CAC TCA ATC CGG ATC GAG GGG GAC 144 Arg Gly Gin Glu Met Tyr Ala Pro His Ser He Arg He Glu Gly Asp 35 40 45 GTC ACC CTC GGG GGG CTG TTC CCC GTA CAC GCC AAG GGT CCC AGC GGA 192 Val Thr Leu Gly Gly Leu Phe Pro Val His Ala Lys Gly Pro Ser Gly 50 55 60 GTG CCC TGC GGC GAC ATC AAG AGG GAA AAC GGG ATC CAC AGG CTG GAA 240 Val Pro Cys Gly Asp He Lys Arg Glu Asn Gly He His Arg Leu Glu 65 70 75 80 GCG ATG CTC TAC GCC CTG GAC CAG ATC AAC AGT GAT CCC AAC CTA CTG 288 Ala Met Leu Tyr Ala Leu Asp Gin He Asn Ser Asp Pro Asn Leu Leu 85 90 95 CCC AAC GTG ACG CTG GGC GCG CGG ATC CTG GAC ACT TGT TCC AGG GAC 336 Pro Asn Val Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 ACT TAC GCG CTC GAA CAG TCG CTT ACT TTC GTC CAG GCG CTC ATC CAG 384 Thr Tyr Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu He Gin 115 120 125 AAG GAC ACC TCC GAC GTG CGC TGC ACC AAC GGC GAA CCG CCG GTT TTC 432 Lys Asp Thr Ser Asp Val Arg Cys Thr Asn Gly Glu Pro Pro Val Phe 130 135 140 GTC AAG CCG GAG AAA GTA GTT GGA GTG ATT GGG GCT TCG GGG AGT TCG 48 Val Lys Pro Glu Lys Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 GTC TCC ATC ATG GTA GCC AAC ATC CTG AGG CTC TTC CAG ATC CCC CAG 52 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Gin He Pro Gin 165 170 175 ATT AGT TAT GCA TCA ACG GCA CCC GAG CTA AGT GAT GAC CGG CGC TAT 57 He Ser Tyr Ala Ser Thr Ala Pro Glu Leu Ser Asp Asp Arg Arg Tyr 180 185 190 GAC TTC TTC TCT CGC GTG GTG CCA CCC GAT TCC TTC CAA GCC CAG GCC 62 Asp Phe Phe Ser Arg Val Val Pro Pro Asp Ser Phe Gin Ala Gin Ala 195 200 205 ATG GTA GAC ATT GTA AAG GCC CTA GGC TGG AAT TAT GTG TCT ACC CTC 67 Met Val Asp He Val Lys Ala Leu Gly Trp Asn Tyr Val Ser Thr Leu 210 215 220 GCA TCG GAA GGA AGT TAT GGA GAG AAA GGT GTG GAG TCC TTC ACG CAG 72 Ala Ser Glu Gly Ser Tyr Gly Glu Lys Gly Val Glu Ser Phe Thr Gin 225 230 235 240 ATT TCC AAA GAG GCA GGT GGA CTC TGC ATT GCC CAG TCC GTG AGA ATC 76 He Ser Lys Glu Ala Gly Gly Leu Cys He Ala Gin Ser Val Arg He 245 250 255 CCC CAG GAA CGC AAA GAC AGG ACC ATT GAC TTT GAT AGA ATT ATC AAA 81 Pro Gin Glu Arg Lys Asp Arg Thr He Asp Phe Asp Arg He He Lys 260 265 270 CAG CTC CTG GAC ACC CCC AAC TCC AGG GCC GTC GTG ATT TTT GCC AAC 86 Gin Leu Leu Asp Thr Pro Asn Ser Arg Ala Val Val He Phe Ala Asn 275 280 285 GAT GAG GAT ATA AAG CAG ATC CTT GCA GCA GCC AAA AGA GCT GAC CAA 912 Asp Glu Asp He Lys Gin He Leu Ala Ala Ala Lys Arg Ala Asp Gin 290 295 300 GTT GGC CAT TTT CTT TGG GTG GGA TCA GAC AGC TGG GGA TCC AAA ATA 960 Val Gly His Phe Leu Trp Val Gly Ser Asp Ser Trp Gly Ser Lys He 305 310 315 320 AAC CCA CTG CAC CAG CAT GAA GAT ATC GCA GAA GGG GCC ATC ACC ATT 1008 Asn Pro Leu His Gin His Glu Asp He Ala Glu Gly Ala He Thr He 325 330 335 CAG CCC AAG CGA GCC ACG GTG GAA GGG TTT GAT GCC TAC TTT ACG TCC 1056 Gin Pro Lys Arg Ala Thr Val Glu Gly Phe Asp Ala Tyr Phe Thr Ser 340 345 350 CGT ACA CTT GAA AAC AAC AGA AGA AAT GTA TGG TTT GCC GAA TAC TGG 1104 Arg Thr Leu Glu Asn Asn Arg Arg Asn Val Trp Phe Ala Glu Tyr Trp 355 360 365 GAG GAA AAC TTC AAC TGC AAG TTG ACG ATT AGT GGG TCA AAA AAA GAA 1152 Glu Glu Asn Phe Asn Cys Lys Leu Thr He Ser Gly Ser Lys Lys Glu 370 375 380 GAC ACA GAT CGC AAA TGC ACA GGA CAG GAG AGA ATT GGA AAA GAT TCC 1200 Asp Thr Asp Arg Lys Cys Thr Gly Gin Glu Arg He Gly Lys Asp Ser 385 390 395 400 AAC TAT GAG CAG GAG GGT AAA GTC CAG TTC GTG ATT GAC GCA GTC TAT 1248 Asn Tyr Glu Gin Glu Gly Lys Val Gin Phe Val He Asp Ala Val Tyr 405 410 415 GCT ATG GCT CAC GCC CTT CAC CAC ATG AAC AAG GAT CTC TGT GCT GAC 1296 Ala Met Ala His Ala Leu His His Met Asn Lys Asp Leu Cys Ala Asp 420 425 430 TAC CGG GGT GTC TGC CCA GAG ATG GAG CAA GCT GGA GGC AAG AAG TTG 1344 Tyr Arg Gly Val Cys Pro Glu Met Glu Gin Ala Gly Gly Lys Lys Leu 435 440 445 CTG AAG TAT ATA CGC AAT GTT AAT TTC AAT GGT AGT GCT GGC ACT CCA 1392 Leu Lys Tyr He Arg Asn Val Asn Phe Asn Gly Ser Ala Gly Thr Pro 450 455 460 GTG ATG TTT AAC AAG AAC GGG GAT GCA CCT GGG CGT TAT GAC ATC TTT 1440 Val Met Phe Asn Lys Asn Gly Asp Ala Pro Gly Arg Tyr Asp He Phe 465 470 475 480 CAG TAC CAG ACC ACA AAC ACC AGC AAC CCG GGT TAC CGT CTG ATC GGG 1488 Gin Tyr Gin Thr Thr Asn Thr Ser Asn Pro Gly Tyr Arg Leu He Gly 485 490 495 CAG TGG ACA GAC GAA CTT CAG CTC AAT ATA GAA GAC ATG CAG TGG GGT 1536 Gin Trp Thr Asp Glu Leu Gin Leu Asn He Glu Asp Met Gin Trp Gly 500 505 510 AAA GGA GTC CGA GAG ATA CCC GCC TCA GTG TGC ACA CTA CCA TGT AAG 1584 Lys Gly Val Arg Glu He Pro Ala Ser Val Cys Thr Leu Pro Cys Lys 515 520 525 CCA GGA CAG AGA AAG AAG ACA CAG AAA GGA ACT CCT TGC TGT TGG ACC 1632 Pro Gly Gin Arg Lys Lys Thr Gin Lys Gly Thr Pro Cys Cys Trp Thr 530 .535 540 TGT GAG CCT TGC GAT GGT TAC CAG TAC CAG TTT GAT GAG ATG ACA TGC 1680 Cys Glu Pro Cys Asp Gly Tyr Gin Tyr Gin Phe Asp Glu Met Thr Cys 545 550 555 560 CAG CAT TGC CCC TAT GAC CAG AGG CCC AAT GAA AAT CGA ACC GGA TGC 1728 Gin His Cys Pro Tyr Asp Gin Arg Pro Asn Glu Asn Arg Thr Gly Cys 565 570 575 CAG GAT ATT CCC ATC ATC AAA CTG GAG TGG CAC TCC CCC TGG GCT GTG 1776 Gin Asp He Pro He He Lys Leu Glu Trp His Ser Pro Trp Ala Val 580 585 590 ATT CCT GTC TTC CTG GCA ATG TTG GGG ATC ATT GCC ACC ATC TTT GTC 1824 He Pro Val Phe Leu Ala Met Leu Gly He He Ala Thr He Phe Val 595 600 605 ATG GCC ACT TTC ATC CGC TAC AAT GAC ACG CCC ATT GTC CGG GCA TCT 1872 Met Ala Thr Phe He Arg Tyr Asn Asp Thr Pro He Val Arg Ala Ser 610 615 620 GGG CGG GAA CTC AGC TAT GTT CTT TTG ACG GGC ATC TTT CTT TGC TAC 1920 Gly Arg Glu Leu Ser Tyr Val Leu Leu Thr Gly He Phe Leu Cys Tyr 625 630 635 640 ATC ATC ACT TTC CTG ATG ATT GCC AAA CCA GAT GTG GCA GTG TGT TCT 196 He He Thr Phe Leu Met He Ala Lys Pro Asp Val Ala Val Cys Ser 645 650 655 TTC CGG CGA GTT TTC TTG GGC TTG GGT ATG TGC ATC AGT TAT GCA GCC 201 Phe Arg Arg Val Phe Leu Gly Leu Gly Met Cys He Ser Tyr Ala Ala 660 665 670 CTC TTG ACG AAA ACA AAT CGG ATT TAT CGC ATA TTT GAG CAG GGC AAG 206 Leu Leu Thr Lys Thr Asn Arg He Tyr Arg He Phe Glu Gin Gly Lys 675 680 685 AAA TCA GTA ACA GCT CCC AGA CTC ATA AGC CCA ACA TCA CAA CTG GCA 211 Lys Ser Val Thr Ala Pro Arg Leu He Ser Pro Thr Ser Gin Leu Ala 690 695 700 ATC ACT TCC AGT TTA ATA TCA GTT CAG CTT CTA GGG GTG TTC ATT TGG 216 He Thr Ser Ser Leu He Ser Val Gin Leu Leu Gly Val Phe He Trp 705 710 715 720 TTT GGT GTT GAT CCA CCC AAC ATC ATC ATA GAC TAC GAT GAA CAC AAG 2208 Phe Gly Val Asp Pro Pro Asn He He He Asp Tyr Asp Glu His Lys 725 730 735 ACA ATG AAC CCT GAG CAA GCC AGA GGG GTT CTC AAG TGT GAC ATT ACA 2256 Thr Met Asn Pro Glu Gin Ala Arg Gly Val Leu Lys Cys Asp He Thr 740 745 750 GAT CTC CAA ATC ATT TGC TCC TTG GGA TAT AGC ATT CTT CTC ATG GTC 2304 Asp Leu Gin He He Cys Ser Leu Gly Tyr Ser He Leu Leu Met Val 755 760 765 ACA TGT ACT GTG TAT GCC ATC AAG ACT CGG GGT GTA CCC GAG AAT TTT 2352 Thr Cys Thr Val Tyr Ala He Lys Thr Arg Gly Val Pro Glu Asn Phe 770 775 780 AAC GAA GCC AAG CCC ATT GGA TTC ACT ATG TAC ACG ACA TGT ATA GTA 2400 Asn Glu Ala Lys Pro He Gly Phe Thr Met Tyr Thr Thr Cys He Val 785 790 795 800 TGG CTT GCC TTC ATT CCA ATT TTT TTT GGC ACC GCT CAA TCA GCG GAA 2448 Trp Leu Ala Phe He Pro He Phe Phe Gly Thr Ala Gin Ser Ala Glu 805 810 815 AAG CTC TAC ATA CAA ACT ACC ACG CTT ACA ATC TCC ATG AAC CTA AGT 2496 Lys Leu Tyr He Gin Thr Thr Thr Leu Thr He Ser Met Asn Leu Ser 820 825 830 GCA TCA GTG GCG CTG GGG ATG CTA TAC ATG CCG AAA GTG TAC ATC ATC 2544 Ala Ser Val Ala Leu Gly Met Leu Tyr Met Pro Lys Val Tyr He He 835 840 845 ATT TTC CAC CCT GAA CTC AAT GTC CAG AAA CGG AAG CGA AGC TTC AAG 259 He Phe His Pro Glu Leu Asn Val Gin Lys Arg Lys Arg Ser Phe Lys 850 855 860 GCG GTA GTC ACA GCA GCC ACC ATG TCA TCG AGG CTG TCA CAC AAA CCC 2 Ala Val Val Thr Ala Ala Thr Met ■Ser Ser Arg Leu Ser His Lys Pro 865 870 875 880 AGT GAC AGA CCC AAC GGT GAG GCA AAG ACC GAG CTC TGT GAA AAC GTA 2 Ser Asp Arg Pro Asn Gly Glu Ala Lys Thr Glu Leu Cys Glu Asn Val 885 890 895 GAC CCA AAC AGC CCT GCT GCA AAA AAG AAG TAT GTC AGT TAT AAT AAC 2 Asp Pro Asn Ser Pro Ala Ala Lys Lys Lys Tyr Val Ser Tyr Asn Asn 900 905 910 CTG GTT ATC TA 2 Leu Val He 915 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 915 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Met Val Gin Leu Arg Lys Leu Leu Arg Val Leu Thr Leu Met Lys Phe 1 5 10 15 Pro Cys Cys Val Leu Glu Val Leu Leu Cys Ala Leu Ala Ala Ala Ala 20 25 30 Arg Gly Gin Glu Met Tyr Ala Pro His Ser He Arg He Glu Gly Asp 35 40 45 Val Thr Leu Gly Gly Leu Phe Pro Val His Ala Lys Gly Pro Ser Gly 50 55 60 Val Pro Cys Gly Asp He Lys Arg Glu Asn Gly He His Arg Leu Glu 65 70 75 80 Ala Met Leu Tyr Ala Leu Asp Gin He Asn Ser Asp Pro Asn Leu Leu 85 90 95 Pro Asn Val Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 Thr Tyr Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu He Gin 115 120 125 Lys Asp Thr Ser Asp Val Arg Cys Thr Asn Gly Glu Pro Pro Val Phe 130 135 140 Val Lys Pro Glu Lys Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Gin He Pro Gin 165 170 175 He Ser Tyr Ala Ser Thr Ala Pro Glu Leu Ser Asp Asp Arg Arg Tyr 180 185 190 Asp Phe Phe Ser Arg Val Val Pro Pro Asp Ser Phe Gin Ala Gin Ala 195 200 205 Met Val Asp He Val Lys Ala Leu Gly Trp Asn Tyr Val Ser Thr Leu 210 215 220 Ala Ser Glu Gly Ser Tyr Gly Glu Lys Gly Val Glu Ser Phe Thr Gin 225 230 235 240 Ile Ser Lys Glu Ala Gly Gly Leu Cys He Ala Gin Ser Val Arg He 245 250 255 Pro Gin Glu Arg Lys Asp Arg Thr He Asp Phe Asp Arg He He Lys 260 265 270 Gin Leu Leu Asp Thr Pro Asn Ser Arg Ala Val Val He Phe Ala Asn 275 280 285 Asp Glu Asp He Lys Gin He Leu Ala Ala Ala Lys Arg Ala Asp Gin 290 295 300 Val Gly His Phe Leu Trp Val Gly Ser Asp Ser Trp Gly Ser Lys He 305 310 315 320 Asn Pro Leu His Gin His Glu Asp He Ala Glu Gly Ala He Thr He 325 330 335 Gin Pro Lys Arg Ala Thr Val Glu Gly Phe Asp Ala Tyr Phe Thr Ser 340 345 350 Arg Thr Leu Glu Asn Asn Arg Arg Asn Val Trp Phe Ala Glu Tyr Trp 355 360 365 Glu Glu Asn Phe Asn Cys Lys Leu Thr He Ser Gly Ser Lys Lys Glu 370 375 380 Asp Thr Asp Arg Lys Cys Thr Gly Gin Glu Arg He Gly Lys Asp Ser 385 390 395 400 Asn Tyr Glu Gin Glu Gly Lys Val Gin Phe Val He Asp Ala Val Tyr 405 410 415 Ala Met Ala His Ala Leu His His Met Asn Lys Asp Leu Cys Ala Asp 420 425 430 Tyr Arg Gly Val Cys Pro Glu Met Glu Gin Ala Gly Gly Lys Lys Leu 435 440 445 Leu Lys Tyr He Arg Asn Val Asn Phe Asn Gly Ser Ala Gly Thr Pro 450 455 460 Val Met Phe Asn Lys Asn Gly Asp Ala Pro Gly Arg Tyr Asp He Phe 465 470 475 480 Gin Tyr Gin Thr Thr Asn Thr Ser Asn Pro Gly Tyr Arg Leu He Gly 485 490 495 Gin Trp Thr Asp Glu Leu Gin Leu Asn He Glu Asp Met Gin Trp Gly 500 505 510 Lys Gly Val Arg Glu He Pro Ala Ser Val Cys Thr Leu Pro Cys Lys 515 520 525 Pro Gly Gin Arg Lys Lys Thr Gin Lys Gly Thr Pro Cys Cys Trp Thr 530 535 540 Cys Glu Pro Cys Asp Gly Tyr Gin Tyr Gin Phe Asp Glu Met Thr Cys 545 550 555 560 Gin His Cys Pro Tyr Asp Gin Arg Pro Asn Glu Asn Arg Thr Gly Cys 565 570 575 Gin Asp He Pro He He Lys Leu Glu Trp His Ser Pro Trp Ala Val 580 585 590 He Pro Val Phe Leu Ala Met Leu Gly He He Ala Thr He Phe Val 595 600 605 Met Ala Thr Phe He Arg Tyr Asn Asp Thr Pro He Val Arg Ala Ser 610 615 620 Gly Arg Glu Leu Ser Tyr Val Leu Leu Thr Gly He Phe Leu Cys Tyr 625 630 635 640 He He Thr Phe Leu Met He Ala Lys Pro Asp Val Ala Val Cys Ser 645 650 655 Phe Arg Arg Val Phe Leu Gly Leu Gly Met Cys He Ser Tyr Ala Ala 660 665 670 Leu Leu Thr Lys Thr Asn Arg He Tyr Arg He Phe Glu Gin Gly Lys 675 680 685 Lys Ser Val Thr Ala Pro Arg Leu He Ser Pro Thr Ser Gin Leu Ala 690 695 700 He Thr Ser Ser Leu He Ser Val Gin Leu Leu Gly Val Phe He Trp 705 710 715 720 Phe Gly Val Asp Pro Pro Asn He He He Asp Tyr Asp Glu His Lys 725 730 735 Thr Met Asn Pro Glu Gin Ala Arg Gly Val Leu Lys Cys Asp He Thr 740 745 750 Asp Leu Gin He He Cys Ser Leu Gly Tyr Ser He Leu Leu Met Val 755 760 765 Thr Cys Thr Val Tyr Ala He Lys Thr Arg Gly Val Pro Glu Asn Phe 770 775 780 Asn Glu Ala Lys Pro He Gly Phe Thr Met Tyr Thr Thr Cys He Val 785 790 795 800 Trp Leu Ala Phe He Pro He Phe Phe Gly Thr Ala Gin Ser Ala Glu 805 810 815 Lys Leu Tyr He Gin Thr Thr Thr Leu Thr He Ser Met Asn Leu Ser 820 825 830 Ala Ser Val Ala Leu Gly Met Leu Tyr Met Pro Lys Val Tyr He He 835 840 845 He Phe His Pro Glu Leu Asn Val Gin Lys Arg Lys Arg Ser Phe Lys 850 855 860 Ala Val Val Thr Ala Ala Thr Met Ser Ser Arg Leu Ser His Lys Pro 865 870 875 880 Ser Asp Arg Pro Asn Gly Glu Ala Lys Thr Glu Leu Cys Glu Asn Val 885 890 895 Asp Pro Asn Ser Pro Ala Ala Lys Lys Lys Tyr Val Ser Tyr Asn Asn 900 905 910 Leu Val He 915 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2769 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (i ) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2769 (D) OTHER INFORMATION: /product= "hmGluR7b' (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: ATG GTC CAG CTG AGG AAG CTG CTC CGC GTC CTG ACT TTG ATG AAG TTC 4 Met Val Gin Leu Arg Lys Leu Leu Arg Val Leu Thr Leu Met Lys Phe 1 5 10 15 CCC TGC TGC GTG CTG GAG GTG CTC CTG TGC GCG CTG GCG GCG GCG GCG 9 Pro Cys Cys Val Leu Glu Val Leu Leu Cys Ala Leu Ala Ala Ala Ala 20 25 30 CGC GGC CAG GAG ATG TAC GCC CCG CAC TCA ATC CGG ATC GAG GGG GAC 14 Arg Gly Gin Glu Met Tyr Ala Pro His Ser He Arg He Glu Gly Asp 35 40 45 GTC ACC CTC GGG GGG CTG TTC CCC GTA CAC GCC AAG GGT CCC AGC GGA 19 Val Thr Leu Gly Gly Leu Phe Pro Val His Ala Lys Gly Pro Ser Gly 50 55 60 GTG CCC TGC GGC GAC ATC AAG AGG GAA AAC GGG ATC CAC AGG CTG GAA 24 Val Pro Cys Gly Asp He Lys Arg Glu Asn Gly He His Arg Leu Glu 65 70 75 80 GCG ATG CTC TAC GCC CTG GAC CAG ATC AAC AGT GAT CCC AAC CTA CTG 28 Ala Met Leu Tyr Ala Leu Asp Gin He Asn Ser Asp Pro Asn Leu Leu 85 90 95 CCC AAC GTG ACG CTG GGC GCG CGG ATC CTG GAC ACT TGT TCC AGG GAC 33 Pro Asn Val Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 ACT TAC GCG CTC GAA CAG TCG CTT ACT TTC GTC CAG GCG CTC ATC CAG 384 Thr Tyr Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu He Gin 115 120 125 AAG GAC ACC TCC GAC GTG CGC TGC ACC AAC GGC GAA CCG CCG GTT TTC 43 Lys Asp Thr Ser Asp Val Arg Cys Thr Asn Gly Glu Pro Pro Val Phe 130 135 140 GTC AAG CCG GAG AAA GTA GTT GGA GTG ATT GGG GCT TCG GGG AGT TCG 48 Val Lys Pro Glu Lys Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 GTC TCC ATC ATG GTA GCC AAC ATC CTG AGG CTC TTC CAG ATC CCC CAG 52 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Gin He Pro Gin 165 170 175 ATT AGT TAT GCA TCA ACG GCA CCC GAG CTA AGT GAT GAC CGG CGC TAT 57 He Ser Tyr Ala Ser Thr Ala Pro Glu Leu Ser Asp Asp Arg Arg Tyr 180 185 190 GAC TTC TTC TCT CGC GTG GTG CCA CCC GAT TCC TTC CAA GCC CAG GCC 62 Asp Phe Phe Ser Arg Val Val Pro Pro Asp Ser Phe Gin Ala Gin Ala ■ 195 200 205 ATG GTA GAC ATT GTA AAG GCC CTA GGC TGG AAT TAT GTG TCT ACC CTC 67 Met Val Asp He Val Lys Ala Leu Gly Trp Asn Tyr Val Ser Thr Leu 210 215 220 GCA TCG GAA GGA AGT TAT GGA GAG AAA GGT GTG GAG TCC TTC ACG CAG 72 Ala Ser Glu Gly Ser Tyr Gly Glu Lys Gly Val Glu Ser Phe Thr Gin 225 230 235 240 ATT TCC AAA GAG GCA GGT GGA CTC TGC ATT GCC CAG TCC GTG AGA ATC 76 He Ser Lys Glu Ala Gly Gly Leu Cys He Ala Gin Ser Val Arg He 245 250 255 CCC CAG GAA CGC AAA GAC AGG ACC ATT GAC TTT GAT AGA ATT ATC AAA 81 Pro Gin Glu Arg Lys Asp Arg Thr He Asp Phe Asp Arg He He Lys 260 265 270 CAG CTC CTG GAC ACC CCC AAC TCC AGG GCC GTC GTG ATT TTT GCC AAC 86 Gin Leu Leu Asp Thr Pro Asn Ser Arg Ala Val Val He Phe Ala Asn 275 280 285 GAT GAG GAT ATA AAG CAG ATC CTT GCA GCA GCC AAA AGA GCT GAC CAA 91 Asp Glu Asp He Lys Gin He Leu Ala Ala Ala Lys Arg Ala Asp Gin 290 295 300 GTT GGC CAT TTT CTT TGG GTG GGA TCA GAC AGC TGG GGA TCC AAA ATA 96 Val Gly His Phe Leu Trp Val Gly Ser Asp Ser Trp Gly Ser Lys He 305 310 315 320 AAC CCA CTG CAC CAG CAT GAA GAT ATC GCA GAA GGG GCC ATC ACC ATT 10 Asn Pro Leu His Gin His Glu Asp He Ala Glu Gly Ala He Thr He 325 330 335 CAG CCC AAG CGA GCC ACG GTG GAA GGG TTT GAT GCC TAC TTT ACG TCC 10 Gin Pro Lys Arg Ala Thr Val Glu Gly Phe Asp Ala Tyr Phe Thr Ser 340 345 350 CGT ACA CTT GAA AAC AAC AGA AGA AAT GTA TGG TTT GCC GAA TAC TGG 11 Arg Thr Leu Glu Asn Asn Arg Arg Asn Val Trp Phe Ala Glu Tyr Trp 355 360 365 GAG GAA AAC TTC AAC TGC AAG TTG ACG ATT AGT GGG TCA AAA AAA GAA 11 Glu Glu Asn Phe Asn Cys Lys Leu Thr He Ser Gly Ser Lys Lys Glu 370 375 380 GAC ACA GAT CGC AAA TGC ACA GGA CAG GAG AGA ATT GGA AAA GAT TCC 12 Asp Thr Asp Arg Lys Cys Thr Gly Gin Glu Arg He Gly Lys Asp Ser 385 390 395 400 AAC TAT GAG CAG GAG GGT AAA GTC CAG TTC GTG ATT GAC GCA GTC TAT 1248 Asn Tyr Glu Gin Glu Gly Lys Val Gin Phe Val He Asp Ala Val Tyr 405 410 415 GCT ATG GCT CAC GCC CTT CAC CAC ATG AAC AAG GAT CTC TGT GCT GAC 1296 Ala Met Ala His Ala Leu His His Met Asn Lys Asp Leu Cys Ala Asp 420 425 430 TAC CGG GGT GTC TGC CCA GAG ATG GAG CAA GCT GGA GGC AAG AAG TTG 1344 Tyr Arg Gly Val Cys Pro Glu Met Glu Gin Ala Gly Gly Lys Lys Leu 435 440 445 CTG AAG TAT ATA CGC AAT GTT AAT TTC AAT GGT AGT GCT GGC ACT CCA 1392 Leu Lys Tyr He Arg Asn Val Asn Phe Asn Gly Ser Ala Gly Thr Pro 450 455 460 GTG ATG TTT AAC AAG AAC GGG GAT GCA CCT GGG CGT TAT GAC ATC TTT 144 Val Met Phe Asn Lys Asn Gly Asp Ala Pro Gly Arg Tyr Asp He Phe 465 470 475 480 CAG TAC CAG ACC ACA AAC ACC AGC AAC CCG GGT TAC CGT CTG ATC GGG 148 Gin Tyr Gin Thr Thr Asn Thr Ser Asn Pro Gly Tyr Arg Leu He Gly 485 490 495 CAG TGG ACA GAC GAA CTT CAG CTC AAT ATA GAA GAC ATG CAG TGG GGT 153 Gin Trp Thr Asp Glu Leu Gin Leu Asn He Glu Asp Met Gin Trp Gly 500 505 510 AAA GGA GTC CGA GAG ATA CCC GCC TCA GTG TGC ACA CTA CCA TGT AAG 158 Lys Gly Val Arg Glu He Pro Ala Ser Val Cys Thr Leu Pro Cys Lys 515 520 525 CCA GGA CAG AGA AAG AAG ACA CAG AAA GGA ACT CCT TGC TGT TGG ACC 163 Pro Gly Gin Arg Lys Lys Thr Gin Lys Gly Thr Pro Cys Cys Trp Thr 530 535 540 TGT GAG CCT TGC GAT GGT TAC CAG TAC CAG TTT GAT GAG ATG ACA TGC 168 Cys Glu Pro Cys Asp Gly Tyr Gin Tyr Gin Phe Asp Glu Met Thr Cys 545 550 555 560 CAG CAT TGC CCC TAT GAC CAG AGG CCC AAT GAA AAT CGA ACC GGA TGC 172 Gin His Cys Pro Tyr Asp Gin Arg Pro Asn Glu Asn Arg Thr Gly Cys 565 570 575 CAG GAT ATT CCC ATC ATC AAA CTG GAG TGG CAC TCC CCC TGG GCT GTG 177 Gin Asp He Pro He He Lys Leu Glu Trp His Ser Pro Trp Ala Val 580 585 590 ATT CCT GTC TTC CTG GCA ATG TTG GGG ATC ATT GCC ACC ATC TTT GTC 182 He Pro Val Phe Leu Ala Met Leu Gly He He Ala Thr He Phe Val 595 600 605 ATG GCC ACT TTC ATC CGC TAC AAT GAC ACG CCC ATT GTC CGG GCA TCT 187 Met Ala Thr Phe He Arg Tyr Asn Asp Thr Pro He Val Arg Ala Ser 610 615 620 GGG CGG GAA CTC AGC TAT GTT CTT TTG ACG GGC ATC TTT CTT TGC TAC 192 Gly Arg Glu Leu Ser Tyr Val Leu Leu Thr Gly He Phe Leu Cys Tyr 625 630 635 640 ATC ATC ACT TTC CTG ATG ATT GCC AAA CCA GAT GTG GCA GTG TGT TCT 196 He He Thr Phe Leu Met He Ala Lys Pro Asp Val Ala Val Cys Ser 645 650 655 TTC CGG CGA GTT TTC TTG GGC TTG GGT ATG TGC ATC AGT TAT GCA GCC 201 Phe Arg Arg Val Phe Leu Gly Leu Gly Met Cys He Ser Tyr Ala Ala 660 665 670 CTC TTG ACG AAA ACA AAT CGG ATT TAT CGC ATA TTT GAG CAG GGC AAG 206 Leu Leu Thr Lys Thr Asn Arg He Tyr Arg He Phe Glu Gin Gly Lys 675 680 685 AAA TCA GTA ACA GCT CCC AGA CTC ATA AGC CCA ACA TCA CAA CTG GCA 21 Lys Ser Val Thr Ala Pro Arg Leu He Ser Pro Thr Ser Gin Leu Ala 690 695 700 ATC ACT TCC AGT TTA ATA TCA GTT CAG CTT CTA GGG GTG TTC ATT TGG 21 He Thr Ser Ser Leu He Ser Val Gin Leu Leu Gly Val Phe He Trp 705 710 715 720 TTT GGT GTT GAT CCA CCC AAC ATC ATC ATA GAC TAC GAT GAA CAC AAG 22 Phe Gly Val Asp Pro Pro Asn He He He Asp Tyr Asp Glu His Lys 725 730 735 ACA ATG AAC CCT GAG CAA GCC AGA GGG GTT CTC AAG TGT GAC ATT ACA 22 Thr Met Asn Pro Glu Gin Ala Arg Gly Val Leu Lys Cys Asp He Thr 740 745 750 GAT CTC CAA ATC ATT TGC TCC TTG GGA TAT AGC ATT CTT CTC ATG GTC 23 Asp Leu Gin He He Cys Ser Leu Gly Tyr Ser He Leu Leu Met Val 755 760 765 ACA TGT ACT GTG TAT GCC ATC AAG ACT CGG GGT GTA CCC GAG AAT TTT 23 Thr Cys Thr Val Tyr Ala He Lys Thr Arg Gly Val Pro Glu Asn Phe 770 775 780 AAC GAA GCC AAG CCC ATT GGA TTC ACT ATG TAC ACG ACA TGT ATA GTA 24 Asn Glu Ala Lys Pro He Gly Phe Thr Met Tyr Thr Thr Cys He Val 785 790 795 800 TGG CTT GCC TTC ATT CCA ATT TTT TTT GGC ACC GCT CAA TCA GCG GAA 24 Trp Leu Ala Phe He Pro He Phe Phe Gly Thr Ala Gin Ser Ala Glu 805 810 815 AAG CTC TAC ATA CAA ACT ACC ACG CTT ACA ATC TCC ATG AAC CTA AGT 24 Lys Leu Tyr He Gin Thr Thr Thr Leu Thr He Ser Met Asn Leu Ser 820 825 830 GCA TCA GTG GCG CTG GGG ATG CTA TAC ATG CCG AAA GTG TAC ATC ATC 2544 Ala Ser Val Ala Leu Gly Met Leu Tyr Met Pro Lys Val Tyr He He 835 840 845 ATT TTC CAC CCT GAA CTC AAT GTC CAG AAA CGG AAG CGA AGC TTC AAG 259 He Phe His Pro Glu Leu Asn Val Gin Lys Arg Lys Arg Ser Phe Lys 850 855 860 GCG GTA GTC ACA GCA GCC ACC ATG TCA TCG AGG CTG TCA CAC AAA CCC 264 Ala Val Val Thr Ala Ala Thr Met Ser Ser Arg Leu Ser His Lys Pro 865 870 875 880 AGT GAC AGA CCC AAC GGT GAG GCA AAG ACC GAG CTC TGT GAA AAC GTA 268 Ser Asp Arg Pro Asn Gly Glu Ala Lys Thr Glu Leu Cys Glu Asn Val 885 890 895 GAC CCA AAC AAC TGT ATA CCA CCA GTA AGA AAG AGT GTA CAA AAG TCT 273 Asp Pro Asn Asn Cys He Pro Pro Val Arg Lys Ser Val Gin Lys Ser 900 905 910 GTT ACT TGG TAC ACT ATC CCA CCA ACA GTA TA 2 6 Val Thr Trp Tyr Thr He Pro Pro Thr Val 915 920 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 922 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Met Val Gin Leu Arg Lys Leu Leu Arg Val Leu Thr Leu Met Lys Phe 1 5 10 15 Pro Cys Cys Val Leu Glu Val Leu Leu Cys Ala Leu Ala Ala Ala Ala 20 25 30 Arg Gly Gin Glu Met Tyr Ala Pro His Ser He Arg He Glu Gly Asp 35 40 45 Val Thr Leu Gly Gly Leu Phe Pro Val His Ala Lys Gly Pro Ser Gly 50 55 60 Val Pro Cys Gly Asp He Lys Arg Glu Asn Gly He His Arg Leu Glu 65 70 75 80 Ala Met Leu Tyr Ala Leu Asp Gin He Asn Ser Asp Pro Asn Leu Leu 85 90 95 Pro Asn Val Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 Thr Tyr Ala Leu Glu Gin Ser Leu Thr Phe Val Gin Ala Leu He Gin 115 120 125 Lys Asp Thr Ser Asp Val Arg Cys Thr Asn Gly Glu Pro Pro Val Phe 130 135 140 Val Lys Pro Glu Lys Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Gin He Pro Gin 165 170 175 He Ser Tyr Ala Ser Thr Ala Pro Glu Leu Ser Asp Asp Arg Arg Tyr 180 185 190 Aεp Phe Phe Ser Arg Val Val Pro Pro Asp Ser Phe Gin Ala Gin Ala 195 200 205 Met Val Asp He Val Lys Ala Leu Gly Trp Asn Tyr Val Ser Thr Leu 210 215 220 Ala Ser Glu Gly Ser Tyr Gly Glu Lys Gly Val Glu Ser Phe Thr Gin 225 230 235 240 He Ser Lys Glu Ala Gly Gly Leu Cys He Ala Gin Ser Val Arg He 245 250 255 Pro Gin Glu Arg Lys Asp Arg Thr He Asp Phe Asp Arg He He Lys 260 265 270 Gin Leu Leu Asp Thr Pro Asn Ser Arg Ala Val Val He Phe Ala Asn 275 280 285 Asp Glu Asp He Lys Gin He Leu Ala Ala Ala Lys Arg Ala Asp Gin 290 295 300 Val Gly His Phe Leu Trp Val Gly Ser Asp Ser Trp Gly Ser Lys He 305 310 315 320 Asn Pro Leu His Gin His Glu Asp He Ala Glu Gly Ala He Thr He 325 330 335 Gin Pro Lys Arg Ala Thr Val Glu Gly Phe Asp Ala Tyr Phe Thr Ser 340 345 350 Arg Thr Leu Glu Asn Asn Arg Arg Asn Val Trp Phe Ala Glu Tyr Trp 355 360 365 Glu Glu Asn Phe Asn Cys Lys Leu Thr He Ser Gly Ser Lys Lys Glu 370 375 380 Asp Thr Asp Arg Lys Cys Thr Gly Gin Glu Arg He Gly Lys Asp Ser 385 390 395 400 Asn Tyr Glu Gin Glu Gly Lys Val Gin Phe Val He Asp Ala Val Tyr 405 410 415 Ala Met Ala His Ala Leu His His Met Asn Lys Asp Leu Cys Ala Asp 420 425 430 Tyr Arg Gly Val Cys Pro Glu Met Glu Gin Ala Gly Gly Lys Lys Leu 435 440 445 Leu Lys Tyr He Arg Asn Val Asn Phe Asn Gly Ser Ala Gly Thr Pro 450 455 460 Val Met Phe Asn Lys Asn Gly Asp Ala Pro Gly Arg Tyr Asp He Phe 465 470 475 480 Gin Tyr Gin Thr Thr Asn Thr Ser Asn Pro Gly Tyr Arg Leu He Gly 485 490 495 Gin Trp Thr Asp Glu Leu Gin Leu Asn He Glu Asp Met Gin Trp Gly 500 505 510 Lys Gly Val Arg Glu He Pro Ala Ser Val Cys Thr Leu Pro Cys Lys 515 520 525 Pro Gly Gin Arg Lys Lys Thr Gin Lys Gly Thr Pro Cys Cys Trp Thr 530 535 540 Cys Glu Pro Cys Asp Gly Tyr Gin Tyr Gin Phe Asp Glu Met Thr Cys 545 550 555 560 Gin His Cys Pro Tyr Asp Gin Arg Pro Asn Glu Asn Arg Thr Gly Cys 565 570 575 Gln Asp He Pro He He Lys Leu Glu Trp His Ser Pro Trp Ala Val 580 585 590 He Pro Val Phe Leu Ala Met Leu Gly He He Ala Thr He Phe Val 595 600 605 Met Ala Thr Phe He Arg Tyr Asn Asp Thr Pro He Val Arg Ala Ser 610 615 620 Gly Arg Glu Leu Ser Tyr Val Leu Leu Thr Gly He Phe Leu Cys Tyr 625 630 635 640 He He Thr Phe Leu Met He Ala Lys Pro Asp Val Ala Val Cys Ser 645 650 655 Phe Arg Arg Val Phe Leu Gly Leu Gly Met Cys He Ser Tyr Ala Ala 660 665 670 Leu Leu Thr Lys Thr Asn Arg He Tyr Arg He Phe Glu Gin Gly Lys 675 680 685 Lys Ser Val Thr Ala Pro Arg Leu He Ser Pro Thr Ser Gin Leu Ala 690 695 700 He Thr Ser Ser Leu He Ser Val Gin Leu Leu Gly Val Phe He Trp 705 710 715 720 Phe Gly Val Asp Pro Pro Asn He He He Asp Tyr Asp Glu His Lys 725 730 735 Thr Met Asn Pro Glu Gin Ala Arg Gly Val Leu Lys Cys Asp He Thr 740 745 750 Asp Leu Gin He He Cys Ser Leu Gly Tyr Ser He Leu Leu Met Val 755 760 765 Thr Cys Thr Val Tyr Ala He Lys Thr Arg Gly Val Pro Glu Asn Phe 770 775 780 Asn Glu Ala Lys Pro He Gly Phe Thr Met Tyr Thr Thr Cys He Val 785 790 795 800 Trp Leu Ala Phe He Pro He Phe Phe Gly Thr Ala Gin Ser Ala Glu 805 810 815 Lys Leu Tyr He Gin Thr Thr Thr Leu Thr He Ser Met Asn Leu Ser 820 825 830 Ala Ser Val Ala Leu Gly Met Leu Tyr Met Pro Lys Val Tyr He He 835 840 845 He Phe His Pro Glu Leu Asn Val Gin Lys Arg Lys Arg Ser Phe Lys 850 855 860 Ala Val Val Thr Ala Ala Thr Met Ser Ser Arg Leu Ser His Lys Pro 865 870 875 880 Ser Asp Arg Pro Asn Gly Glu Ala Lys Thr Glu Leu Cys Glu Asn Val 885 890 895 Asp Pro Asn Asn Cys He Pro Pro Val Arg Lys Ser Val Gin Lys Ser 900 905 910 Val Thr Trp Tyr Thr He Pro Pro Thr Val 915 920 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 630 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..630 (D) OTHER INFORMATION: /product= "partial hmGluR6' (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: GTG GAG GCC CTG CAG TGG TCT GGC GAC CCC CAC GAG GTG CCC TCG TCT 4 Val Glu Ala Leu Gin Trp Ser Gly Asp Pro His Glu Val Pro Ser Ser 1 5 10 15 CTG TGC AGC CTG CCC TGC GGG CCG GGG GAG CGG AAG AAG ATG GTG AAG 9 Leu Cys Ser Leu Pro Cys Gly Pro Gly Glu Arg Lys Lys Met Val Lys 20 25 30 GGC GTC CCC TGC TGT TGG CAC TGC GAG GCC TGT GAC GGG TAC CGC TTC 14 Gly Val Pro Cys Cys Trp His Cys Glu Ala Cys Asp Gly Tyr Arg Phe 35 40 45 CAG GTG GAC GAG TTC ACA TGC GAG GCC TGT CCT GGG TAC ATG AGG CCC 19 Gin Val Asp Glu Phe Thr Cys Glu Ala Cys Pro Gly Tyr Met Arg Pro 50 55 60 ACN CCC AAC CAC ATC NNA CTT NNG CCC ACA CCT GTG GTG CGC CTG AGC 24 Xaa Pro Asn His He Xaa Leu Xaa Pro Thr Pro Val Val Arg Leu Ser 65 70 75 80 TGG TCC TCC CCC TGG GCA GCC CCG CCG CTC CTC CTG GCC GTG CTG GGC 28 Trp Ser Ser Pro Trp Ala Ala Pro Pro Leu Leu Leu Ala Val Leu Gly 85 90 95 ATC GTG GCC ACT ACC ACG GTG GTG GCC ACC TTC GTG CGG TAC AAC AAC 33 He Val Ala Thr Thr Thr Val Val Ala Thr Phe Val Arg Tyr Asn Asn 100 105 110 ACG CCC ATC GTC CGG GCC TCG GGC CGA GAG CTC AGC TAC GTC CTC CTC 38 Thr Pro He Val Arg Ala Ser Gly Arg Glu Leu Ser Tyr Val Leu Leu 115 120 125 ACC GGC ATC TTC CTC ATC TAC GCC ATC ACC TTC CTC ATG GTG GCT GAG 43 Thr Gly He Phe Leu He Tyr Ala He Thr Phe Leu Met Val Ala Glu 130 135 140 CCT GGG GCA GCG GTC TGT GCC GCC CGC AGG CTC TTC CTG GGC CTG GGC 48 Pro Gly Ala Ala Val Cys Ala Ala Arg Arg Leu Phe Leu Gly Leu Gly 145 150 155 160 ACG ACC CTC AGC TAC TCT GCC CTG CTC ACC AAG ACC AAC CGT ATC TAC 52 Thr Thr Leu Ser Tyr Ser Ala Leu Leu Thr Lys Thr Asn Arg He Tyr 165 170 175 CGC ATC TTT GAG CAG GGC AAG CGC TCG GTC ACA CCC CCT CCC TTC ATC 57 Arg He Phe Glu Gin Gly Lys Arg Ser Val Thr Pro Pro Pro Phe He 180 185 190 AGC CCC ACC TCA CAG CTG GTC ATC ACC TTC AGC CTC ACC TCC CTG CAG 62 Ser Pro Thr Ser Gin Leu Val He Thr Phe Ser Leu Thr Ser Leu Gin 195 200 205 GTG GGG 63 Val Gly 210 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 210 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Val Glu Ala Leu Gin Trp Ser Gly Asp Pro His Glu Val Pro Ser Ser 1 5 10 15 Leu Cys Ser Leu Pro Cys Gly Pro Gly Glu Arg Lys Lys Met Val Lys 20 25 30 Gly Val Pro Cys Cys Trp His Cys Glu Ala Cys Asp Gly Tyr Arg Phe 35 40 45 Gin Val Asp Glu Phe Thr Cys Glu Ala Cys Pro Gly Tyr Met Arg Pro 50 55 60 Xaa Pro Asn His He Xaa Leu Xaa Pro Thr Pro Val Val Arg Leu Ser 65 70 75 80 Trp Ser Ser Pro Trp Ala Ala Pro Pro Leu Leu Leu Ala Val Leu Gly 85 90 95 He Val Ala Thr Thr Thr Val Val Ala Thr Phe Val Arg Tyr Asn Asn 100 105 110 Thr Pro He Val Arg Ala Ser Gly Arg Glu Leu Ser Tyr Val Leu Leu 115 120 125 Thr Gly He Phe Leu He Tyr Ala He Thr Phe Leu Met Val Ala Glu 130 135 140 Pro Gly Ala Ala Val Cys Ala Ala Arg Arg Leu Phe Leu Gly Leu Gly 145 150 155 160 Thr Thr Leu Ser Tyr Ser Ala Leu Leu Thr Lys Thr Asn Arg He Tyr 165 170 175 Arg He Phe Glu Gin Gly Lys Arg Ser Val Thr Pro Pro Pro Phe He 180 185 190 Ser Pro Thr Ser Gin Leu Val He Thr Phe Ser Leu Thr Ser Leu Gin 195 200 205 Val Gly 210

Claims: Claims 1. Purified human metabotropic glutamate receptor (hmGluR) which is a member of the hmGluR4 subfamily. 2. A receptor of the hmGluR4 subfamily according to claim 1 characterized in that its amino acid sequence is more than about 65 % identical, particularly about 70 % identical, to the sequence of hmGluR4 set forth in SEQ ID NO:2. 3. Receptor according to claim 1 selected from the group consisting of hmGluR4, hmGluR7 and hmGluRό. 4. Receptor according to claim 2 which is a hmGluR4 subtype. 5. Receptor according to claim 2 which is the hmGluR4 subtype having the amino acid sequence set forth in SEQ ID NO:2. 6. Receptor according to claim 2 which is a hmGluR7 subtype. 7. Receptor according to claim 2 which is a hmGluR7 subtype selected from the group consisting of hmGluR7a having the amino acid sequence set forth in SEQ ID NO: 12 and hmGluR7b having the amino acid sequence set forth in SEQ ID NO: 14. 8. Receptor according to claim 2 which is a hmGluR7 subtype comprising a polypeptide selected from the group consisting of the polypep tides having the amino acid sequences set forth in SEQ ID NOs. 6, 8 and 10, respectively. 9. Receptor according to claim 2 which is a hmGluRό subtype. 10. Receptor according to claim 2 which is a hmGluRό subtype comprising a polypeptide having the amino acid sequence set forth in SEQ ID NO: 16. 11. Variant of a receptor according to any of claims 1 to 10. 12. Composition of matter comprising a receptor of any of claims 1 to 11. 13. Process for the preparation of a receptor of any of claims 1 to 11 comprising multiplication of a suitable host cell in vitro or in vivo. 14. Use of a receptor according to any of claims 1 to 11 for screening of a compound which modulates the activity of said receptor. 15. Nucleic acid comprising a nucleic acid coding for a receptor according to any of claims 1 to claim 11, or a fragment of said nucleic acid. 16. Nucleic acid according to claim 15, which is a DNA. 17. A DNA according to claim 16 selected from the group consisting of the DNAs having substantially the nucleotide sequences set forth in SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13 and 15, respectively. 18. Nucleic acid probe comprising at least 14 contiguous bases of the DNA according to claim 16 or 17, or the complement thereof. 19. Process for the preparation of a nucleic acid according to claim 16. 20. A DNA according to claim 17 which is a hybrid vector. 21. A host cell comprising a DNA of claim 17. 22. A eukaryotic host cell expressing the DNA of claim 17. 23. A host cell transfected with a DNA of claim 20. 24. A host cell according to claim 23 which is a mammalian cell. 25. Use of a host cell according to claim 22 for the screening of a compound which modulates the activity of a receptor according to claim 1. 26. Process for the preparation of a host cell according to claim 21. 27. Purified mRNA complementary to the DNA according to claim 7. 28. A method for identifying DNA encoding a hmGluR subtype according to claim 1 comprising: contacting human DNA with a probe according to claim 18, and identifying DNA(s) which substantially hybridize to said probe. 29. A method for identifying compounds binding to a hmGluR subtype comprising use of a receptor protein according to claim 1 in a competitive binding assay. 30. An assay for identifying compounds whcih modulate the activity of a hmGluR subtype according to claim 1 comprising - contacting the cells of claim 22 with at least one compound or signal whose ability to modulate the activity of said receptor subtype is sought to be determined, and subsequently - analyzing cells for a difference in functional response attributable to said receptor. 31. Assay according to claim 30 comprising - contacting the cells of claim 22 with at least one compound or signal whose ability to modulate the second messenger activity of a receptor subtype of the invention is sought to be determined, and subsequently - monitoring said cells for a change in the level of a particular second messenger. 32. A method for modulating the signal transduction activity of a hmGluR subtype according to claim 1 comprising contacting said subtype with an effective amount of at least one compound identified in the assay of claim 31. 33. An agonist, antagonist or allosteric modulator identified by the assay of claim 30. 34. A modulator of a hmGluR subtype according to claim 1 identified by the assay of claim 30. 35. A method for detecting a glutamate agonist or an allosteric modulator of a hmGluR subtype according to claim 1 having agonistic activity comprising the steps of (a) exposing a compound to a hmGluR subtype of the invention coupled to a response pathway, under conditions and for a time sufficient to allow interaction of the compound with the receptor and an associated response through the pathway, and (b) detecting an increase or decrease in the stimulation of the response pathway resulting from the interaction of the compound with the hmGluR subtype, relative to the absence of the tested compound and therefrom determining the presence of an agonist or an allosteric modulator having agonist-like activity. 36. A method for identifying a glutamate antagonist or an allosteric modulator of a hmGluR subtype according to claim 1 having antagonistic activity, said method comprising the steps of (a) exposing a compound in the presence of a known glutamate agonist to a hmGluR subtype of the invention coupled to a response pathway, under conditions and for a time sufficient to allow interaction of the agonist with the receptor and an associated response through the pathway, and (b) detecting an inhibition of the stimulation of the response pathway by the agonist resulting from the interaction of the test compound with the hmGluR subtype, relative to the stimulation of the response pathway induced by the glutamate agonist alone, and therefrom determining the presence of a glutamate antagonist or an allosteric modulator having antagonist-like activity. 37. An antibody directed against a protein of claim 1. 38. An antibody according to claim 37 which is a polyclonal antibody. 39. An antibody according to claim 37 which is a monoclonal antibody. 40. A method for modulating the signal transduction activity of a hmGluR subtype according to claim 1 comprising contacting said receptor with an antibody of claim 35. 41. A receptor according to claim 1 obtainable by recombinant DNA technology. 42. A fusion protein comprising a receptor according to any of claims 1 to 11.

Inventors: FLOR PETER JOSEF, KNOEPFEL THOMAS, KUHN RAINER, LINDAUER KRISTIN, PUETTNER IRENE, FLOR, PETER, JOSEF, KNOEPFEL, THOMAS, KUHN, RAINER, LINDAUER, KRISTIN, PUETTNER, IRENE
Applicants: CIBA GEIGY AG, FLOR PETER JOSEF, KNOEPFEL THOMAS, KUHN RAINER, LINDAUER KRISTIN, PUETTNER IRENE, CIBA-GEIGY AG, FLOR, PETER, JOSEF, KNOEPFEL, THOMAS, KUHN, RAINER, LINDAUER, KRISTIN, PUETTNER, IRENE
Application year: 1994
Main classification: C12N15
IPC codes: C07K14, C07K16, C07K19, C12N1, C12N5, C12N15, C12P21, C12Q1, C12R1, G01N33